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Resumo 
O processamento da extremidade 3’ do pré-mRNA é um importante 
mecanismo de regulação genética, e grande parte dos genes em mamíferos apresenta 
mais do que um possível local de poliadenilação, produzindo diferentes moléculas de 
mRNA e contribuindo para a heterogeneidade transcricional. Os locais de 
poliadenilação alternativos (PAS) podem localizar-se em intrões ou diferentes exões, 
produzindo diferentes isoformas proteicas, ou serem restritos ao 3’ UTR, alterando o 
comprimento deste e por conseguinte locais de ligação de factores proteicos ou alvos 
de microRNAs. A poliadenilação alternativa (APA) é regulada ao nível da cromatina e 
mRNA, e pode ser influenciada por diferentes condições biológicas, como 
diferenciação celular, desenvolvimento e cancro. 
CD5 é uma glicoproteína transmembranar constitutivamente expressa em 
linfócitos T e num subgrupo de linfócitos B, B1a. O CD5 tem uma função inibitória na 
activação do TCR e BCR, e a sua desregulação desencadeia uma resposta imune 
deficiente. 
As extremidades 3’ do CD5 foram mapeadas numa linha tumoral de células T 
(Jurkat) e foram identificadas três principais isoformas de mRNA, diferindo no 
comprimento do 3' UTR – pA1, pA2 e pA3. A isoforma mais curta (pA1), produzida por 
PAS teoricamente mais fracos, é a mais expressa tanto em células Jurkat como 
células T primárias, enquanto a isoforma mais longa, produzida pelo uso do PAS 
teoricamente mais forte, e a menos expressa. No entanto, as proporções das 
diferentes isoformas variam entre os dois tipos de células. A isoforma pA3 apresenta 
uma maior percentagem em células primárias, enquanto a isoforma pA2 é favorecida 
em células Jurkat. Curiosamente, esta isoforma apresentou a maior eficiência de 
tradução num trabalho anterior, nestas mesmas células, sugerindo um mecanismo de 
optimização de produção de proteína. 
A estreita relação entre a tradução e os mecanismos de processamento de 
mRNA traduz-se nas múltiplas funções das proteínas intervenientes. O papel de 
factores de splicing na APA do CD5 foi investigado através de knockdown por siRNA, 
e foi possível mostrar que a proteína PTB favorece a selecção do sinal pA1 e inibe o 
uso do sinal pA2, e que SRSF6 favorece o sinal pA1 mas inibe o sinal pA3. Mostrou-se 
também que as regiões vizinhas dos três PAS têm diferentes padrões de ligação de 
proteínas. O estado da cromatina também mostrou influenciar a APA do CD5, uma vez 
que baixos níveis de acetilação aumentam o uso das isoformas pA2 e pA3. 
Os nossos resultados sugerem que o CD5 é fortemente regulado pela APA 
através de vários mecanismos distintos. 
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Abstract 
Alternative pre-mRNA 3’ end processing plays a major role in gene expression 
and most mammalian genes have multiple polyadenylation (pA) sites that can be 
differentially selected, thus contributing to the enrichment of the transcriptional 
heterogeneity. The alternative pA signals (PAS) can be located in an internal exon or 
an intron, yielding different protein isoforms, or be positioned in tandem at the 3’ UTR, 
resulting in mRNAs with different 3’ UTR lengths, with the inclusion or exclusion of 
binding sites for specific RNA binding proteins (RBPs) or microRNA target sites. APA is 
regulated at the chromatin and mRNA levels, and may vary under specific conditions, 
such as cellular differentiation, development and cancer.  
CD5 is a transmembrane glycoprotein with three scavenger receptor cysteine 
rich (SRCR) domains, constitutively expressed in T-cells and in a subset of B-cells, 
B1a cells. CD5 has an inhibitory function in the TCR and BCR activation and its 
deregulation triggers a defective immune response.  
We mapped the mRNA 3’ ends of CD5 in a Jurkat T cell line and identified three 
major mRNA isoforms differing in the 3’ UTR length – pA1, pA2 and pA3. The shortest 
isoform (pA1), defined by the predicted weakest PAS, is the most expressed one, both 
in Jurkat and primary T cells, while the longest isoform (pA3), defined by the canonical 
PAS, is the least expressed. Even though, the proportions of the different CD5 APA 
isoforms vary in the two cell types. The pA3 isoform presents a higher percentage in 
primary T cells, relative to Jurkat, while the pA2 isoform is favored in Jurkat cells. 
Surprisingly, this is the most efficiently translated isoform, as reported in a previous 
work, which suggests a protein production optimization mechanism. 
The tight relation between the different mRNA processing mechanisms and 
transcription relies on activity of protein factors that often play multiple functions. We 
investigated the role of splicing factors in CD5 APA by siRNA knockdown, and we 
showed that PTB favors the selection of the pA1 signal and inhibits the usage of the 
pA2 signal, and that SRSF6 also favors the pA1 signal but inhibits the pA3 signal. 
Moreover, we showed that the surrounding regions of the three PAS have different 
patterns of binding of RNA binding proteins. The chromatin state also showed to 
influence CD5 APA, as low levels of acetylation increase the usage of pA2 and pA3 
isoforms.  
Our results suggest that CD5 is regulated by APA through several distinct 
mechanisms, and that they may work together in a PAS specific manner. 
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Introduction 
 
The Immune System and Adaptive Response 
The immune system refers to all the structures and processes that protect an 
organism from biological invaders or chemical elements which could cause a disease. 
It is composed of two different types of defense, one less specific and other more 
specific, with different functions and timing of response. The less specific system, 
innate immunity, is the first line of defense against a broad set of pathogens and 
includes anatomic and physiologic barriers, the inflammatory process and the cellular 
response through specialized cells performing phagocytosis [1].  
The adaptive immune system is the second line of defense and can recognize 
and eliminate specific foreign molecules and microorganisms – antigens. This system 
is highly diverse and specific as it can identify billions of antigens. It also distinguishes 
self from non-self-antigens, preventing autoimmune responses. The other main feature 
is the immunologic memory in which, after the first encounter with an antigen, memory 
cells specific for that antigen are maintain in the blood circulation so that in a second 
encounter the system can produce a faster and stronger response [1]. 
The main players in the adaptive immune system are the B and T lymphocytes. 
The B lymphocytes differentiate and maturate within the bone marrow and, when 
activated, perform the humoral immune response, which consists in the release of 
antibodies to the bloodstream that neutralize the antigens and activate other immune 
pathways. T lymphocytes differentiate and maturate in the thymus, where they start to 
express the T cell membrane receptor (TCR) which recognizes specific antigens linked 
to major histocompatibility complex (MHC) membrane molecules. There are two major 
classes of these molecules, class I that is expressed by nearly all nucleated cells and 
class II that is expressed only by the antigen-presenting cells (macrophages, B 
lymphocytes and dendritic cells). The T helper (TH) cells, which express the CD4 
membrane glycoprotein, interact with antigen–class II MHC molecule complexes and 
are activated to secrete different cytokines in order to induce the activity of other cells, 
such as macrophages and B cells. On the other hand, T cytotoxic (TC) cells, which 
express the CD8 membrane glycoprotein, interact with antigen–class I MHC molecule 
complexes and, in the presence of specific cytokines, differentiate into cytotoxic T 
lymphocytes (CTL). These have cytotoxic or killing activity against the foreign antigen–
class I MHC molecule complexes presenting cells, such as infected or tumor cells. For 
the correct antigen recognition and T cell activation several accessory receptors are 
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needed besides the TCR and CD4/CD8, that are involved in the strength of the bond 
between T cells and the antigen-presenting cells or/and in the signal transduction [1]. 
 
  
The CD5 molecule 
CD5 is one of the accessory receptors referred above, with the function of 
regulating the immune response in T and B lymphocytes. Much attention has been 
channeled to the study of this molecule in the last 20 years, although little is known 
about the CD5 expression regulation. This understanding is essential for therapeutic 
research since this molecule is associated with several pathological processes. 
The human CD5 is a type I transmembrane (single pass molecule with the 
C-terminal directed to the cytoplasm) glycoprotein with a 67 kDa molecular mass [2]. It 
is a member of the highly conserved scavenger receptor cysteine rich (SRCR) 
superfamily, containing in its extracellular region three SRCR domains. Its domains are 
classified as type B, along with the SRCR domains of CD6 and Spα, for example, 
characterized by the presence of 8 cysteine residues and being encoded by a single 
exon (in contrast, type A domains contain 6 cysteine residues and are encoded by 
more than one exon) [3]. The SRCR domains are retained in the natural soluble CD5 
form identified in the human serum, proposed to be originated by proteolytic cleavage 
[4]. The CD5 gene is located in chromosome 11q13 and contains 11 exons and 10 
introns (Ensembl). After cleavage of the 24 amino acid residues (aa) signal peptide, the 
extracellular region is composed of 348 aa with the three SRCR domains encoded by 
exons 3, 5 and 6. The transmembrane domain of 30 aa is encoded by exon 7 and the 
intracellular region composed by the last 93 aa is encoded by exons 8 to 10 (predicted 
regions from NCBI and UniProt). 
In humans, CD5 is constitutively expressed in thymocytes and mature T 
lymphocytes, but is restricted to a subpopulation of B lymphocytes, B1a cells [5, 6]. 
This subpopulation represents most of the B cells in the fetus and umbilical cord blood, 
but it decreases with age representing only 10-25% in the peripheral blood and slightly 
higher percentages in the peritoneal cavity and tonsil [6, 7]. CD5 is also expressed in a 
recently described regulatory B cells subset in mice, CD1dhiCD5+ B cells [21]. 
In B-cell, the pan-B cell surface molecule CD72 [8] and the VH framework 
regions of immunoglobulins or Fab fragments [9] showed to interact with CD5. Also 
expressed in activated T cells, a molecule different from CD72 was identified to interact 
with CD5, CD5L (CD5 ligand) [10]. Other molecules have been shown to interact with 
the extracellular region of CD5, but it was not yet identified a consensual physiological 
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relevant CD5 ligand. Moreover, Brown and Lacey showed that CD5 can interact with 
itself through species specific homophilic binding [11]. 
 
The intracellular region is highly conserved between human and mouse [12] 
and contains specific motifs involved in signal transduction, suggesting an important 
role for this region that may be associated with CD5 function. Of the four potential 
tyrosine phosphorylation sites, residues Y429 and Y463 showed to be phosphorylated, 
probably by the protein tyrosine kinase Lck, after T cell activation [13]. Along with 
Y441, Y429 is part of an imperfect immunoreceptor tyrosine-based activation motif 
(ITAM) [13]. The membrane-proximal residue Y378, located at an imperfect 
immunoreceptor tyrosine-based inhibition motif (ITIM), showed to associate with the 
protein tyrosine phosphatase SHP-1 and inhibit the TCR/CD3 activity [14]. Serine 
residues S458, S459 and S461, located at the C-terminal region, are phosphorylation 
targets of the casein kinase II (CKII), which in turn showed to be associated with 
inhibition of T cell activity [15, 16]. Other molecules such as c-CBL [17, 18] and Ras 
GTPase activating protein (RasGAP) [18] also showed to associate with CD5. 
 
CD5 functions 
Although was initially thought that CD5 functioned as a positive signal receptor 
[19, 20], it was later characterized as an inhibitory effector. Accumulating evidence 
support this function, such as CD5-deficient mice show higher T cell proliferation and 
hyperresponsive thymocytes to stimulation through the TCR [21, 22], and T cells with 
low CD5 levels present exaggerated TCR-induced activation [23]. CD5 co-localizes 
with the CD3/TCR complex in the immunological synapse and showed to decrease the 
calcium response [14, 24]. Moreover, CD5 stimulation increases Fyn phosphorylation, 
which in turn inhibits ZAP70, an important factor in the TCR signaling cascade [25].  
CD5 is expressed since the earliest thymic progenitors to the mature 
T lymphocytes [5, 26]. The hematopoietic progenitors that arrive to the thymus with no 
T-cell specific surface markers (TCR and CD4 or CD8) – double negatives (DN)  – 
express low levels of CD5 in a TCR-independent manner [5]. In the following stages, 
CD5 expression becomes modulated by the pre-TCR and TCR activity [26]: as DN 
cells differentiate into double positive (DP) cells (simultaneous expression of CD4 and 
CD8), CD5 expression increases and is maintained in an intermediate level by the low 
affinity pre-TCR/MHC interaction [5]; as DP cells became single positives (SP), they 
undergo positive selection, by which the ones unable to recognize the self–MHC 
molecules are eliminated, and depending on the MHC recognized, I or II, become 
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engaged to the CD8 or CD4 lineage; the next step is negative selection, when those 
that have an abnormal strong reaction to the self-MHC or recognize self-antigens are 
also eliminated [1, 27]. The inhibitory activity of CD5 appears affect the choice of the 
negative or positive selected thymocytes. For example, thymocytes that do not bind 
self-MHC or do so with very low affinity are eliminated in the presence of CD5, instead 
of being incorrectly positively selected [26]. On the other hand, it was shown that 
positively selected thymocytes with high affinity TCR/MHC interaction upregulate CD5 
and that in its absence, are instead eliminated [26]. Azzam et al. proposed that CD5 
has a regulatory function in these selection processes in a TCR’s clonotypes specific 
manner, promoting a tendency to sort high affinity TCRs to form active and useful 
mature T cells. So, although CD5 knockdown mice show no significant changes in 
thymocyte maturation, different groups of thymocytes undergo a fate shift either 
favoring positive selection or negative selection [5, 26]. 
Given CD5 function in the selection of the TCR repertoire during T cell 
differentiation and the control of the TCR activation threshold in mature T cells, this 
molecule presents itself as an important regulator of the T cells tolerance, and its 
deregulation can lead to an exaggerate immune response [23].  
Furthermore, the CD5 effect in T cell activity seems to have consequences in 
the activation-induced cell death (AICD), a homeostatic mechanism that controls the 
pool of activated T cells and induces T cell tolerance [28]. AICD is the process by 
which activated T cells overexpress Fas and its ligand (FasL), which activate caspases 
and pro-apoptotic effectors, leading to cell death [1]. Friedlein et al. showed that 
tumor-reactive circulating T cells expressed higher levels of CD5 than tumor-infiltrating 
lymphocytes (TIL) and, in fact, the first cells also expressed lower levels of FasL and 
caspase-8. Therefore, these CD5high lymphocytes were less susceptible to AICD, and 
this feature could be reversed by incubation with an anti-CD5 mAb [28], but also 
showed weaker Ca2+ response facing tumor cells than TIL [29]. To overcome the tumor 
evasion, it seems that TIL decrease the CD5 levels to adjust their sensitivity and 
increase the tumor-specific T cell response, although it renders them more susceptible 
to AICD [30]. 
In B1a cells, the immune response mediated by the BCR is also negatively 
regulated by CD5 [31]. These cells characteristically produce natural IgM with low 
affinity polyreactivity to auto-antigens, and high levels of the anti-inflammatory cytokine 
IL-10 [32].  
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CD5 and human disorders 
The B1a cells have been associated with several autoimmune models. 
Experimental autoimmune encephalitis (EAE) and inflammatory bowel disease are two 
examples of autoimmune models that showed a protective role of these cells through 
the production of the anti-inflammatory cytokine IL-10 [29, 33]. In contrast, the B1a 
cells production of natural polyreactive antibodies for auto-antigens and enhanced 
antigen-presenting ability are two features that seem to contribute to autoimmune 
processes [33, 34]. Also, the role of CD5 in the regulation of the TCR activation was 
associated with a protective function of CD5 in an EAE model [35]. 
As described above, CD5 is involved in the antitumor immune response, but is 
also associated with specific neoplastic disorders. The most striking example is the B 
cell chronic lymphocytic leukaemia (B-CLL), which is characterized by an accumulation 
of CD5 positive B cells, with increased levels of survival factors and IL-10, that 
enhances B cell proliferation, stimulated by a CD5 and PKC (phosphorylation of protein 
kinase C) dependent signaling pathway [29, 36]. 
 
 
3’ end processing 
For most of the eukaryotic mRNAs to be stable, able to be exported from the 
nucleus and be correctly translated, the pre-mRNA molecules must undergo a series of 
co-transcriptional modifications to become mature mRNAs. These modifications are the 
5’ capping, addition of a 7-methylguanosine (m7G) to the 5' end of the pre-mRNA; the 
splicing, removal of introns and ligation of the exons, including the 5’ and 
3’ untranslated regions (5’ and 3’ UTR); and 3’ end processing. In this thesis, we will 
focus on this last mechanism, also referred as polyadenylation, and how its regulation 
can influence gene expression.  
Polyadenylation is a widespread mechanism in eukaryotes [37, 38], although it 
does not generally happen in rRNAs (ribosomal RNA), and is less consensual in 
prokaryotes [39, 40]. It is a co-transcriptional two step mechanism consisting in the 
endonucleolytic cleavage of the pre-mRNA and polymerization of a poly(A) (adenosine 
monophosphate) tail [41, 42]. This tail can have between 250 and 300 adenosines in 
humans, but it may vary in a specie-specific manner, and its size functions as a mark 
for degradation [43]. The cleavage site in the pre-mRNA, pA site, is defined by several 
cis-elements that function as binding sites for essential cleavage and polyadenylation 
factors. The pA site region is composed by an A-rich hexamer, the pA signal (PAS), an 
U/GU-rich downstream sequence element (DSE), and U-rich upstream sequence 
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elements (USE) [42]. The canonical PAS is the AAUAAA sequence, present in almost 
60% of the human pre-mRNAs, but several variants are also used, such as AUUAAA in 
~15% and other single nucleotide variants of the hexamer in ~12% of the cases [44]. 
This hexamer is located 10-30 nt upstream of the pre-mRNA cleavage site and is 
recognized by the CPSF (cleavage and polyadenylation specific factor), while the DSE 
is recognized by the CstF (cleavage stimulation factor) [42]. The binding of these two 
proteins recruits other important factors, as CFI and CII (cleavage factors I and II) and 
PAP (polyadenylation polymerase), to compose the polyadenylation core machinery 
[42]. The CTD (carboxy-terminal domain) of the RNA polymerase II (RNAP II) is also 
important, being required as a recruiter and platform for necessary pA factors [45]. As 
for the cleavage site, it is characteristically immediately downstream of a YA 
(pyrimidine-adenine) motif but it can vary in several nucleotides upstream or 
downstream depending on the exact position of the defining sequences referred 
above [46]. 
 
 
Alternative Polyadenylation 
Every mRNA molecule produced is the result of a pA site selection undertake 
by the transcription/RNA processing machinery. This process is called alternative 
polyadenylation (APA). This phenomenon is observed in more than 70% of all 
mammalian, Saccharomyces cerevisiae and Arabidopsis thaliana’s genes and about 
half of the genes of Drosophila, Zebrafish and C. elegans [47, 48]. Furthermore, many 
genes present the same pattern, in which the most distal PAS is a stronger consensual 
PAS, such as the canonical hexamer AAUAAA, and the most proximal is a weaker and 
less conserved sequence. This distribution suggests that distal PAS function as a 
default mechanism to ensure the transcription termination and mRNA 3’ end 
processing and therefore the correct maturation of the mRNA [47].  
 
Types of APA 
There are two main types of APA: UTR-APA, in which the alternative PAS are 
located only in the 3’ UTR, leading to mRNA isoforms differing on the 3’ UTR length 
without affecting the coding region, and CR-APA (coding region APA), which yields 
mRNA isoforms with different coding regions [49]. The last type is subdivided in three 
categories: alternative terminal exon APA, in which alternative splicing removes a PAS 
altering the last exon; intronic APA, in which a cryptic intronic PAS is used when a 
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5’ splicing site is skipped [47]; and internal exon APA, in which an alternative PAS in 
located in an internal exon (Fig. 1) [50]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CR-APA alters the protein sequence in a qualitative manner, while 
UTR-APA can affect gene expression through mRNA stability, translation efficiency 
and localization, by changing the available miRNA target sites and RBPs binding sites 
in the 3’UTR, that regulate these processes [51]. 
 
 
APA modulation in biological processes 
It has been extensively reported that APA is a dynamic mechanism as the 
alternative mRNA isoforms are differently expressed under different biological 
conditions. In the last ten years, starting with EST data, several results of genome-wide 
analysis have been published, showing tendencies in the pattern of the usage of 
alternative PAS in a tissue-specific manner and in specific biological conditions. For 
example, transcripts of the nervous system, brain, bone marrow and uterus have a 
preferential usage of the distal PAS, while in retina, ovary, placenta and blood the most 
proximal PAS are used [52]. This distribution seems to indicate a preference of the 
longest mRNA isoforms in tissues associated with cellular differentiation and the 
shortest in tissues associated with cell proliferation. In fact, Sandberg et al. showed a 
Figure 1. Types of APA mechanisms based on the classification by Elkon et al., 2013. UTR-APA refers to the presence 
of alternative PAS in tandem in the 3’ UTR; CR-APA refers to alternative PAS localized in different exons or introns that 
leads to different coding sequences. Figure adapted from Tian and Manley, 2013. 
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global shortening of the mRNA isoforms after activation of murine TH cells associated 
with the proliferation state and increased gene expression, and further showed that in 
some cases, full-length 3’ UTR displayed less protein expression [53]. Moreover, Jin 
and Tian showed that induction of dedifferentiation of a somatic cell to a pluripotent 
stem cell was accompanied by a global 3’ UTR shortening, while the contrary showed a 
global lengthening [54]. An overall concept was thus constructed indicating that 
proliferation, dedifferentiation and cell transformation states are associated with usage 
of the proximal PAS, and development and differentiation states are associated with 
usage of the distal PAS [49].  
 
APA in diseases 
There are already described examples of APA involved in human diseases, 
particularly mutations that lead to a loss or gain of PAS function, or their strengthening 
or weakening. IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) 
is caused by different mutations and deletions of the FOXP3 gene. A mutation in the 
first PAS (AAUAAA → AAUGAA), which is skipped, increases the usage of the distal 
PAS, and yields a less stable mRNA isoform that reduces the protein expression of the 
transcription factor FOXP3 [55].  
The proto-oncogene cyclin D1 has two major mRNA isoforms: the longer one 
results from a 3’ UTR PAS, cyclin D1a, and the shorter one results from alternative 
splicing that retains an intron with intronic PAS, cyclin D1b [56]. The shorter isoform 
lacks an important phosphorylation site essential for the nuclear exportation, and the 
protein retention in the nucleus is associated with higher transformation capacity [57]. 
Also, point mutations showed to create a premature PAS in the cyclin D1a isoform 
3’ UTR, which was associated with bad prognostic in mantle cell lymphoma (MCL) 
patients [58]. Similarly to cyclin D1, it has been observed a global 3’ UTR shortening, 
especially in proto-oncogenes, in cancers in comparison to normal tissues, that seems 
to strongly associate with the proliferation maintenance of the cells [47, 59]. 
There is also some evidence of the influence of APA in various endocrine 
diseases [60]. For example, higher usage of the transcription factor 7-like 2 (TCF7L2) 
proximal PAS seems associated with higher risk of type 2 diabetes. 
 
 
Regulation of APA 
Several levels of regulation contribute to the selection of the PAS to use by the 
cellular machinery. The cis-elements composing the PAS define a strong or weak 
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signal, the protein factors, trans-elements, influence its usage, and chromatin features 
modulate RNAP II transcription and “reading” of the region comprising the PAS (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cis-elements 
As mentioned above, the sequences that define the pre-mRNA cleavage site 
include the PAS hexamer and regions upstream and downstream of the signal. The 
canonical sequence AAUAAA is the most efficiently processed and the most frequently 
used [44, 61], but the PAS “strength”, or efficiency, is also dependent on the 
surrounding regions [61]. For example, Nunes et al. showed that mutations in the DSE 
of the melanocortin 4 receptor (MC4R) lead to much stronger effects on the 3’ end 
processing efficiency, than the mutation of the respective PAS [62]. Moreover, less 
efficiently processed PAS variants are frequently surrounded by conserved U- and 
UG-rich regions, promoting the binding of 3’ end processing factors or other 
trans-elements [49]. In APA, the usage of the non-canonical PAS is more frequent than 
in single PAS genes [44, 62], and the proximal PAS are usually non-canonical, while 
the distal pA sites use canonical signals [44]. The use of these supposedly weak PAS 
may facilitate their regulation in APA [44].  
 
 
 
Figure 2. Levels of APA regulation comprise chromatin features, the cis-sequences and protein factors. Figure adapted 
from Di Giammartino et al, 2011. 
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Trans-elements 
Since the pre-mRNA processing occurs co-transcriptionally, the trans-elements 
that influences APA are not only the 3’ end processing factors, but also protein factors 
involved in transcription and in the other pre-mRNA processing mechanisms (see APA 
and Transcription and APA and Splicing).  
As for the core polyadenylation factors, their upregulation and downregulation 
was observed in the global 3’ UTR shortening described in proliferating cells and the 
lengthening in differentiating cells [54, 63]. Limiting levels of these factors may favor 
the usage of stronger PAS, while the presence of higher levels can allow the usage of 
a weaker PAS [49]. One of the most revisited examples is the effect of the CstF-64 
levels, a CstF subunit, in the IgM APA regulation [64]. A secreted isoform of IgM is 
produced by usage of an intronic PAS and Takagaki et al. showed that an increase of 
CstF-64 concentrations in activated B cells favor the use of the weaker proximal 
intronic PAS. It is now established that IgM pre-mRNA processing is a complex 
process, depending not only on CstF levels, but also in competition between the 
alternative splicing and polyadenylation mechanisms [65]. It was also shown that a set 
of genes coding for 3’ end processing factors contain in their promoters the E2F 
transcription factor binding site, and that decreased levels of this factor reduced the 
cleavage at the proximal PAS  [66]. These and other studies suggested that 
overexpression of the 3’ end processing machinery leads to higher usage of the 
weaker, proximal PAS, namely during proliferation. Despite it, it seems more correct to 
take factor-specific conclusions, since there are studies that show opposite effects for 
specific factors, as for example the CFIm68 subunit [67]. 
 
Chromatin modulation 
APA is also regulated at the DNA level, particularly by chromatin structure and 
epigenetic marks [50], similarly to the transcription and splicing processes. Spies et al. 
identified a strong nucleosome depletion at the PAS and an enrichment downstream, 
and that these two features were stronger in highly used PAS [68]. This data raised the 
hypothesis that the nucleosome enrichment downstream of the PAS had a role in 
slowing down the RNAP II in that region, promoting its higher usage [69]. The PAS 
nucleosome depletion was confirmed in a later study that associated this observation 
with proximal (in case of APA) and unique PAS [70]. Nevertheless, it is still unknown if 
this depletion is due to the characteristic sequences of the PAS (adenines and 
thymines), which show lower intrinsic nucleosome affinity, or if it is a consequence of 
another yet unidentified factor, such as a DNA-binding protein with a 
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nucleosome-excluding function [49]. A role for epigenetic marks in APA has been 
suggested, since some examples of genetic imprinting modulating APA were 
described, such as the Herc3-Nap1l5 case [71]. Nap1l5 is a retrogene located in an 
intron of the host gene Herc3 that is expressed in the paternal allele, while in the 
maternal allele its promoter is methylated and thus silenced. In the paternal allele the 
host gene uses a PAS upstream of Nap1l5, whilst in the maternal allele it uses a 
downstream PAS. Changes in the methylation state of the Nap1l5 promoter can alter 
the usage of the two alternative types of PAS of Herc3, which further indicates a 
coupling between RNAP II transcription and APA.  
Beside particular examples, global epigenetic marks are also associated with 
PAS regions, such as the increase of the transcriptional repression marks H3K9me3 
and H3R2me2 marks around the PAS [69]. Also, the activation mark H3K36me3, which 
seems correlated with slower RNAP II elongation rate [72], was shown to be decreased 
downstream of the PAS, even strongly in PAS that are highly used [69]. These data 
supports a role for chromatin structure in APA regulation. 
 
 
APA and Transcription 
Although it has been proven that transcription termination is independent of the 
mRNA 3’ end processing, it is well known that both processes are intimately connected 
[41, 73]. In fact, RNAP II transcription termination depends on functional PAS [74]. 
Several 3’ end processing factors bind the RNAP II CTD [75], such as CPSF, which is 
recruited since the beginning of transcription by the transcription factor TFIID to RNAP 
II CTD at the promoter [76], and the yeast Pcf11p subunit of CF IA [77]. The CTD 
functions as a platform and recruiter, and therefore, is considered a member of the 
3’ end processing machinery [75, 78]. But the interaction between transcription and 
3’ end processing is not restricted to the CTD. As Nagaike et al. demonstrated, 
transcription elongation factors, such as PAF1c (RNAP II-associated factor), can 
enhance the mRNA 3’ end processing, and its upregulation causes a usage switch to 
the proximal PAS [79]. 
Other important feature of transcription that influences APA is the RNAP II 
elongation rate, as shown by Pinto et al. using a Drosophila strain with a point mutation 
in the larger subunit of RNAP II. This mutation renders the RNAP II 50% slower and 
promotes the usage of the proximal PAS in six genes, including polo [80]. Moreira 
proposed that the deceleration of RNAP II allows the proximal PAS to be longer 
exposed to the 3’ end processing machinery facilitating its usage rather than the distal 
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PAS [81]. This model is consistent with the epigenetic data mentioned above, which 
shows that chromatin marks that slow RNAP II are present near the PAS, particularly in 
high usage PAS. 
 
 
APA and Splicing 
Similar to transcription, the splicing mechanism also influences APA. It is easy 
to correlate these two mechanisms since splicing is directly involved in two types of 
CR-APA, alternative terminal exon APA and intronic APA (see Types of APA), by 
excluding or exposing an exonic or intronic PAS. 
Components of the spliceosome, such as U1 and U2 small nuclear 
ribonucleoproteins (snRNP) and U2 auxiliary factor (U2AF), have individually shown a 
role in APA. In knockdown studies of U1, which recognizes the 5’ splicing site of the 
intron, it was observed that, not only it repressed splicing, but also promoted premature 
polyadenylation in cryptic intronic PAS [82]. Interestingly, the consequent 
polyadenylation was splicing-independent, as the knockdown of other spliceosome 
components did not show the same effect. Moreover, it is known that U1 can interact 
with and inhibit PAP [83], and that also binds to the COX-2 proximal PAS USE [84]. A 
recent wide-genome analysis indicates that U1 plays an important role in APA, as it 
showed that this molecule protects proximal PAS and its decrease is associated with 
mRNA 3’ UTR shortening [85]. U2 also interacts with PAP, while the auxiliary factor 
U2AF interacts with CPSF and CFI, and both showed to promote a correct 3’ end 
processing [86]. 
 
 
3’ end processing, APA and RBPs 
The mRNA processing is also regulated by RBPs and several of them are 
involved in splicing have shown to be also implicated in APA. One example is NOVA2, 
a neuron-specific splicing factor RBP, with already identified binding sites in 3’ UTRs. 
When its site is located within 30 nt of the PAS, NOVA2 inhibits its recognition by the 
3’ end processing machinery, while when it is located in distal elements it promotes the 
PAS usage [87]. A triplet-repeat expansion in the polyadenylation binding protein 
nuclear I (PABPNI) gene causes autosomal-dominant oculopharyngeal muscular 
dystrophy (OPMD) [88] and it seems to relate to APA deregulation, since mutations or 
knockdown of PABPN1 induces a global shift to proximal PAS usage [89]. Other 
example is the Drosophila embryonic-lethal abnormal visual system (ELAV) protein, 
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which was shown to directly bind and repress the proximal PAS, therefore promoting 
the distal PAS usage in neuronal tissues [90]. 
The hnRNPs (heterogeneous nuclear ribonucleoproteins) are proteins that form 
RNA-protein complexes with the pre-mRNA molecules in the nucleus, and can assist in 
the correct mRNA processing, nuclear export and metabolism. Several hnRNPs have 
been associated with 3’ end processing regulation (review in [86]), such as hnRNP F, L 
and H. A particularly important hnRNP in this work is the hnRNP I, also known as PTB 
(polypyrimidine tract-binding protein). This protein was first reported to bind to the USE 
element of the C2 (complement 2) gene by Moreira et al., and be required for efficient 
pA site cleavage [91]. It was also shown correct levels of PTB in the cells were 
determinant for 3’ end processing, as PTB knockdown led to decrease in pA site 
cleavage, but it was also shown that overexpression of PTB induced a similar outcome 
followed by reduced levels of mRNA [92]. Castelo-Branco et al. thus proposed a 
specific model for PTB in the C2 polyadenylation: its positive function may be due to 
recruitment of essential 3’ end processing factors when PTB levels are balanced; high 
PTB levels cause a negative effect in polyadenylation, as PTB competes with CstF 
that, in the case of the C2 pre-mRNA that lacks a DSE, also binds to the USE. 
Hall-Pogar et al. and Danckwardt et al. showed that PTB also binds to the USE of 
COX-2 and prothrombin encoding genes, respectively, playing a role in the correct 3’ 
end processing [84, 93]. The PTB 3’ end processing stimulating mechanisms were 
further clarified when Millevoi et al. showed that PTB facilitates the hnRNP H binding to 
G-rich auxiliary elements upstream and downstream of the PAS which in turn 
stimulates the assembly of 3’ end processing factors (PAP and CstF), promoting both 
cleavage and polyadenylation [94]. PTB acts as an auxiliary factor for 
cleavage/polyadenylation, but was also recently associated with APA of the 
beta-adducin encoding gene [95]. This gene undergoes APA in a tissue-specific 
manner and PTB was shown to bind the DSE of the distal PAS, which when deleted 
induces a shift to higher usage of the cryptic PAS. 
Other important family of RNA-binding proteins with functions in splicing is the 
serine/arginine-rich (SR) protein family, which are currently identified as SRSFs 
(serine/arginine-rich splicing factors). Some members of this protein family have 
already been associated also with APA. SRSF1, 2, 5 and 6 (ASF/SF2, SC35, SRp40 
and SRp55, respectively) were shown to modulate PAS selection independently of 
alternative splicing in the glial fibrillary acidic protein (GFAP) APA [96]. Also, in a Rous 
sarcoma virus (RSV) model, Srp20 and ASF/SF2 showed to promote polyadenylation 
possibly through interaction with a specific CFI domain [97, 98], and in a later study, 
Srp20 was associated with transcription termination [99].  
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Several more RBPs have been identified as APA regulators, operating through 
a myriad of different interactions and mechanisms. For example, they can compete 
with 3’ end processing factors for binding sites, promote or avoid their recruitment, 
redirect them to alternative PAS, alter the spatial redistribution or favor post-
transcriptional modifications that alter the factors activity [86]. Furthermore, RBPs 
interact with miRNAs in a bilateral regulation relation, as miRNAs can regulate RBPs 
expression and vice-versa, and can present a specific interconnection or have a 
wide-spread effect [100, 101]. 
 
 
Aims 
The main goal of this thesis is to gain knowledge about the factors that 
modulate and control the usage of different PAS, and its consequences in gene 
expression. CD5 has been increasingly studied in lymphoproliferative and autoimmune 
disorders contexts, and its importance in these processes has been successively 
supported. Nevertheless, insight about its expression regulation is still lacking, which 
could be essential for the understanding of the pathophysiology of such diseases. It 
was known that CD5 contained at least two alternative PAS in the 3’UTR, and thus it is 
a good candidate to explore APA. Therefore, we proposed to: 
 Map the 3’ ends of the CD5 mRNA isoforms to confirm the already 
reported PAS and/or identify new ones, in T cells; 
 Compare the relative use of each PAS in different cellular contexts, as 
primary T cells versus a cancer cell line and resting versus activated T cells; 
 Investigate the effect of different chromatin states in the CD5 APA and 
correlate it with PAS usage; 
 Identify protein factors, in particular among those with functions in 
splicing, which influence the CD5 APA, supporting the close involvement of the two 
processes. 
With these goals we hope to shed some light on the molecular mechanisms 
behind CD5 APA regulation.  
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Material and Methods 
 
In silico analysis 
Primers were designed using the Primer-BLAST platform of NCBI, and further 
analyzed in the OligoAnalyzer 3.1 of Integrated DNA Technologies (eu.idtdna.com). 
Predicted RNA-binding proteins binding sites were searched using the SFmap 
predictor. Sequence alignments and pairwise identity percentages were obtained using 
the default settings of MUSCLE 3.6 running in Geneious v4.8. 
 
Jurkat E6.1 cell culture 
E6.1 cells were grown and maintained in 1X Roswell Park Memorial Institute 
(RPMI) 1640 Medium, GlutaMAX™, supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin (all reagents 
from Gibco). They were incubated at 37° C with 5% CO2, in T75 culture flasks and 
passed at a 1:6 ratio, every 2-3 days, maintaining a 0.5-2.5x106 cells/mL concentration.  
 
T cell activation 
Twenty four hours after E6.1 cells had been passed, they were activated by 
incubation with PHA (phytohemagglutinin) (Sigma-Aldrich) for 48h at a 10 µg/mL 
concentration. 
 
Primary T cells extraction 
First, we extracted PBMCs (Peripheral Blood Mononuclear Cells), including 
monocytes, macrophages and lymphocytes, with the Lympholyte®-H reagent 
(Cedarlane Laboratories). We used defibrinated blood from healthy donor, kindly 
provided by the Blood Collection Center of Hospital de S. João, Porto. The extraction 
was performed following the manufacturer’s protocol, with the layering of the blood 
over the Lympholyte®-H reagent, and without platelets removal.  
From the PBMCs sample, the T lymphocytes were purified, using the 
EasySepTM Human CD4+ T cell Enrichment Kit (StemCell), following the Manual 
EasySepTM protocol using the purple Easysep™ magnet. The obtained cells were 
diluted in 5 mL of 1X PBS (Phosphate buffered saline). 
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TSA treatment and RNA fractionation  
After extraction of the primary T lymphocytes, they were incubated with TSA 
(Trichostatin A) for 1h at a 0.5 µM concentration. Cells were collected, washed twice 
with 1X PBS and resuspended in 1 mL of RSB buffer (10 mM Tris pH 7.4, 10 mM NaCl 
and 3 mM MgCl2). After 3 min incubation on ice, cells were centrifuged at 4000 rpm for 
3 min at 4 ºC, and the supernatant was discarded. The pellet was resuspended in 150 
µL of RSBG40 buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 10% glycerol, 
0.5% NP-40, 0.5 mM DTT (Invitrogen) and 100U/mL RiboLock RNase Inhibitor 
(Thermo Scientific)). Cells were centrifuged at 7000 rpm for 3 min at 4 ºC. We analyzed 
the RNA nuclear fraction, since the short TSA incubation time only causes an effect in 
the recently transcribed mRNAs. Therefore, the supernatant (cytoplasmatic fraction) 
was discarded and the nuclei pellet was used to RNA extraction. In every experiment, 
non-treated T cells, i.e. resting cells, were submitted to the same incubation time with 
DMSO (solvent of TSA) and fractionation protocol. 
 
Cell counts 
A Countess® Automated Cell Counter (Invitrogen) was used to count cells, with 
10 µL of a 1:1 mixture of cell suspension and 0.4% Trypan blue (Invitrogen). 
 
RNA extraction and quantification 
E6.1 cells RNA was extracted with the PureLinkTM RNA Mini Kit (Ambion), 
following the manufacturer’s protocol, and with DNase treatment performed by the 
On-column PureLink™ DNase Treatment Protocol. The 80 µL DNase mixture 
contained 0.25 U/µL DNase I recombinant, 1X Incubation buffer (both reagents from 
Roche) and RNase-free water. RNA was diluted in 30-50 µL of RNase-free water. 
RNA was quantified by NanoDropTM 1000 Spectrophotometer (Thermo 
Scientific), using RNase-free water as blank. 
 
qRT(Reverse Transcription)-PCR 
cDNA synthesis 
cDNA was synthesized in a reaction containing 0.4 to 1 μg of RNA, 5 U/μL 
SuperScript® III Reverse Transcriptase (Invitrogen), 1 U/μL RiboLock RNase Inhibitor 
(Thermo Scientific), 1X First-Strand Buffer (Invitrogen), 5 mM DTT (Invitrogen), 2.5 M 
Random Hexamers (5’-NNNNNN-3’; Sigma-Aldrich), 0.5 mM dNTPs mix (Thermo 
Scientific) and RNase-free water up to 20 μL. First, the water, RNA, Random 
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Hexamers and dNTPs were mixed and incubated 5 min at 65 ºC to denature the RNA 
and primers, followed by cooling in ice for 5 min. Then, the rest of the Freagents were 
added and the reaction was incubated 5 min at 25 ºC to extend primers, 60 min at 
50 ºC to extend cDNA strands and 15 min at 70 ºC to inactivate the reaction, in a 48-
well TPersonal Thermocycler (Biometra). 
 
qPCR (Real-time PCR) 
All primer pairs used were first optimized. The optimization consists in 
performing qPCR reactions as described below, using a series of dilutions (1:10) of a 
cDNA template, to construct a standard curve. In a perfect reaction, in each cycle (n) 
the DNA doubles, so the dilution factor will equal 2n. For an ideal efficiency the slope of 
a standard curve generated with 10-fold dilutions would be -3.32. The slope obtained is 
used to calculate the primer pair efficiency (E) with Formula 1 and the correspondent 
efficiency percentage (% E) with Formula 2 (Real-Time PCR Applications Guide, 
Bio-Rad). Different annealing temperatures and primers concentrations were tested in 
order to obtain the best primer efficiency between 1.9 and 2.1 (90-110%). 
 
 
 
 
 
The quantification of the CD5 isoforms (see CD5 mRNA isoforms expression in 
Results) and the knockdown tests of the siRNA assays (all primers in Table 3) were 
performed by qPCR. Each reaction contained 1 µL of the synthesized cDNA, 1X iQ™ 
SYBR® Green Supermix (Bio-Rad) and distilled deionized water (ddH2O) up to 20 μL, 
with variable concentrations of primers: 
 
 
 
 
Reactions were incubated in the StepOne Real-time PCR System (Applied 
Biosystems) thermocycler with the following program: 3 min at 95 ºC; 40 cycles of 
CD5 mRNA isoforms quantification Knockdown tests 
total pA pA2+3 pA3 18S Specific splicing factor primers 18S 
0.25 μM 0.25 μM 0.15 μM 0.25 μM 0.125 μM 0.125 μM 
Table 1. Primers concentrations for the different qPCR reactions. Forward and reverse primers with the same shown 
concentration.  
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20 sec at 95 °C and 20 sec at the respective annealing temperature; and 81 cycles 
increasing 0.5 ºC at each 10 sec starting at 55 ºC. 
The endogenous control chosen was the housekeeping gene 18S based on the 
literature and considering that was the one showing the more consistent amplification 
(comparing with GAPDH and β-actin) [102, 103]. The results were analyzed using the 
“ΔCt method” and “ΔΔCt method”, assuming the maximum efficiency (E = 2), since the 
results do not suffer significant changes when using the real efficiencies. The “ΔCt 
method” generates the expression of the target gene (TG) relative to the endogenous 
control (reference gene – RG) (Formulae 3a and 3b). These expression levels were 
also used to generate ratios between the longer isoforms and the total mRNA levels 
[80]. The “ΔΔCt method” additionally normalizes the expression level for a specific 
sample (SS) relatively to a reference sample (RS) (non-treated or scramble transfected 
cells) (Formula 4 when considering E = 2). This method generates a normalized fold 
expression, in which values > 1 translate higher expression of the target gene in the 
specific sample relatively to the reference sample, while values < 1 translate lower 
expression. 
 
 
 
 
 
 
 
3’ RACE (Rapid Amplification of cDNA Ends) 
cDNA synthesis 
To map the 3’ ends of CD5 mRNA isoforms, cDNA was synthesized from 1 µg 
of DNase treated RNA extracted from E6.1 cells. The reaction contained 5 U/μL 
SuperScript® III Reverse Transcriptase (Invitrogen), 1 U/μL RiboLock RNase Inhibitor 
(Thermo Scientific), 2 μL of First-Strand Buffer 5X (Invitrogen), 3 mM DTT (Invitrogen), 
0.6 mM dNTPs mix (Thermo Scientific), and 0.6 µM Poly(dT) adaptor primer and 
RNase-free water up to 16.5 μL. The RNA, RNase-free water, dNTPs mix and poly(dT) 
adaptor primer were incubated for 5 min at 65 ºC and 5 min on ice. The rest of the 
components were added and the total reaction was incubated 55 min at 50 ºC and 
15 min at 75 ºC. 
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First PCR reaction 
To 2 μL of the cDNA obtained with poly(dT) adaptor primer, it was added 1X 
Phusion HF Buffer, 0.012 U/μL Phusion DNA Polymerase (Thermo Scientific), 0.1 µM 
RACE Fw1 primer, 0.1 µM Universal anchor primer, 0.2 mM dNTPs mix (Thermo 
Scientific) and ddH2O up to 50 μL. The thermocycler program was: 1 min at 98 ºC; 35 
cycles of 15 sec at 98 ºC, 15 sec at 62 ºC and 1 min at 72 ºC; 7 min at 72 ºC. The 
reaction product was analyzed by 1.5% agarose gel electrophoresis stained with 
SybrSafe DNA gel stain (Invitrogen) and using the GeneRuler DNA Ladder Mix 
(Thermo Scientific). 
 
Nested PCR reaction 
From 2 μL of the previous reaction product, a nested PCR was performed using 
the same protocol and program as the first reaction, but using the RACE Fw2 primer. 
The product was also analyzed by agarose gel electrophoresis, as described above. 
 
3’ RACE using the SMARTerTM RACE kit 
The SMARTerTM RACE cDNA Amplification kit (Clontech) was used to 
synthesized cDNA, using SMARTScribe™ Reverse Transcriptase, and perform the first 
and nested 3’ RACE reactions, using the Phusion DNA Polymerase (Thermo 
Scientific), following the manufacturer’s protocols. The forward primers, RACE kit Fw1 
and RACE kit Fw2 (Table 3), were designed according to kit protocol’s specificities. 
 
mRNA isoforms sequencing 
Cloning of the 3’ RACE product 
Firstly, 15 μL of the PCR product from the nested 3’ RACE reaction was 
incubated with 10 pmol of dATP (Thermo Scientific) and 1 U of GoTaq® DNA 
Polymerase (Promega), for 10 min at 72 ºC. Secondly, this product was purified using 
the QIAquick PCR Purification Kit (Qiagen), following the manufacturer’s protocol “PCR 
purification using a microcentrifuge”. Finally, the purified PCR product with addition of 
dATP was then cloned into the pCR®2.1-TOPO® vector using reagents from the TOPO® 
TA Cloning® Kit. To 5 μL of DNA, 0.5 μL of vector and 0.5 μL of Salt Solution were 
added and incubated 20 min at room temperature. 
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Transformation of competent TOP10 E. coli cells 
Heat shock competent TOP10 E. coli cells were transformed with the prepared 
plasmid DNA, in a 10:1 ratio (5 µL of plasmid DNA to 50 µL of bacteria). This mixture 
was incubated on ice for 10 min followed by heat shock at 42° C for 1 min and 10 min 
on ice. After adding 4X LB (Lysogeny broth) medium, the mixture was incubated at 37° 
C, allowing the cells to start their growth and stabilize. After ~30 min, cells were 
centrifuged at 3.000 rpm for 2 min. Most of the supernatant was discarded and cells 
were carefully resuspended in the remaining liquid. The suspension was plated in 
50 μg/ml kanamycin LB plates with 20 μL of X-Gal 50 mg/mL and incubated at 37 ºC in 
a shaker incubator, overnight. 
 
Colony PCR and Plasmid DNA extraction 
From de previous plates, white positive and blue negative colonies were 
submitted to colony PCR. The reaction consisted in 0.3 U of GoTaq® DNA Polymerase, 
1X Green GoTaq® Reaction Buffer (Promega), 5 mM MgCl2 (Promega), 1 μM M13 
forward and reverse primers (Table 3), 0.4 mM dNTPs mix and ddH2O up to 10 μL. 
With a sterile toothpick, the selected colony is dipped into the PCR tube and 
subsequently used to inoculate new kanamycin LB plates, incubated 37 ºC overnight. 
From the positive colonies, the ones with different sizes are selected and inoculated in 
liquid LB medium with 500 μg/ml kanamycin.  
Plasmid DNA was extracted from the suspension cultures using the PureLink® 
Quick Plasmid Miniprep Kit (Invitrogen), following the manufacturer’s protocol, and 
samples were sequenced outside the lab. 
 
Flow cytometry 
To quantify surface protein levels of CD69 and CD5 in the E6.1 cell line, cells 
were collected, washed with 1X PBS and resuspended in 1X PBS containing 0.2% 
BSA and 0.1% Sodium Azide (PBS/BSA/azide buffer). For each condition and antibody 
(Ab), 1x106 cells/well were incubated with the respective Ab, following manufacturers’ 
instructions, in 96-well plates, for 25 min on ice. The anti-CD69 Ab, and respective 
isotype control, were primary labeled, so after the incubation cells were washed twice 
and resuspended in 400 μL of the PBS/BSA/azide buffer in FACS tubes. The anti-CD5 
Ab, and respective isotypes controls, were unlabeled, so after the first incubation, cells 
were washed twice with the PBS/BSA/azide buffer, followed by incubation with the 
secondary labeled Ab, for 25 min on ice. After the second incubation, cells were 
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washed twice and resuspended in 400 μL of the PBS/BSA/azide buffer. Cells were 
filtered and analyzed in a FACSCalibur (Becton Dickinson). 
 
Antibodies 
The antibodies used in the FACS experiments were: Anti-Human CD5 (Y2/178), 
Mouse Monoclonal IgG1 (Santa Cruz Biotechnology); Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/RPE Rabbit F(ab’)2 (Dako); Mouse IgG1 K Isotype Control (BD 
Pharmingen); Anti-Human CD69 APC, Mouse Monoclonal IgG1 K (eBioscince); Mouse 
IgG1 K Isotype Control APC (eBioscince). 
 
E6.1 cells siRNA transfection 
Two siRNAs (small interference RNAs) for each target and the scramble 
sequence (GenePharma), as negative control, from Sigma-Aldrich (Table 2), were 
transfected into 1x106 E6.1 cells per condition. The Amaxa® Cell Line Nucleofector® Kit 
V and the Nucleofector® Device, with the X-005 program, were used, following the 
manufacturer’s protocol. siRNAs concentration and time of incubation were optimized 
for each knockdown target (Table 2). 
 
 
 
 
 
Nuclear protein extracts 
E6.1 cells nuclear protein extracts were prepared using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents, following the manufacturer’s protocol. The 
extracts were separated in a 12% SDS-PAGE gel, to confirm its integrity.  
 
 
 
 
siRNA 1 
(sense sequence) 
siRNA 2 
(sense sequence) 
siRNA 
concentration 
Incubation 
time 
PTB GCACAGUGUUGAAGAUCAU[dT][dT] AACUUCCAUCAUUCCAGAGAA[dT][dT] 50 nM 48 h 
SRSF3 CGAAGUGUGUGGGUUGCUA[dT][dT] GAGAAGUGGUGUACAGGAA[dT][dT] 150 nM 48 h 
SRSF6 GUUACUCUUCCAUGUUUAU[dT][dT] GAACAUCUGGCAGAGACAA[dT][dT] 150 nM 48 h 
Scramble UUCUCCGAACGUGUCACGU[dT][dT] - 48 h 
Table 2. siRNAs sense sequences (5’ – 3’), concentration (nM) and time of incubation (h), for each KD target, for  
Jurkat cells transfection with the Amaxa® Cell Line Nucleofector® Kit V. The concentration used for the scramble is 
equal to the maximum concentration of the siRNAs used simultaneously. 
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UV cross-linking assays 
In vitro transcription templates 
Using E6.1 cDNA, three sequences around each CD5 PAS, were amplified 
using the GoTaq® DNA Polymerase and the 5X Colorless GoTaq® Reaction Buffer 
(Promega), in a 150 μL PCR reaction, following the manufacturer’s protocol. Each 
forward primer contained the T7 promoter at its 5’ end. PCR products were separated 
in a 1% agarose gel to confirm the amplification of only one band, correspondent to the 
selected sequence. The PCR products were purified using the QIAquick PCR 
Purification Kit (Qiagen), following the manufacturer’s protocol “PCR purification using 
a microcentrifuge”. 
 
In vitro transcription of radiolabeled RNA 
The radiolabeled RNA sequences were transcribed in reactions with 500 ng of 
the template DNA, 0.5x Transcription Optimized Buffer (Promega), 16 U of T7 RNA 
polymerase (Promega), 10 mM DTT (Promega), 0.4 mM rATP and rGTP, 12 µM rCTP, 
0.08 mM rUTP (Thermo Scientific), 20 μCi [α-32P] CTP, 20 μCi [α-32P] UTP 
(PerkinElmer) and RNse-free water up to 12.5 μL. The reactions were incubated 2 h at 
37ºC. The radiolabeled probes were purified by illustra ProbeQuant G-50 Micro 
Columns (GE Healthcare), following the manufacturer’s protocol. 
 
UV cross-linking 
Each RNA probe, 1000 cpm (counts per minute), was incubated with the 30 µL 
of prepared E6.1 cells nuclear extracts, in a reaction containing 30 mM HEPES pH 7.9, 
1.56 mM MgCl2, 0.5 mM ATP, 20 mM Creatine Phosphate and 2.5% polyvinyl alcohol 
(PVA). Samples were incubated 20 min at 30 ºC and UV cross-linked in Hoefer UVC 
500 UV Crosslinker (254 nm, 9 min, 4 cm from light source) on ice. Five µL of Ambion® 
RNase Cocktail™, containing 2.5 U of RNase A and 100 U of RNase T1, were added 
to each reaction, and incubated at 37ºC for 30 min.  
 
Immunoprecipitation (IP) of PTB 
Thirty µL of the previous UV cross-linked reactions (inputs) were incubated with 
5 µL of the anti-Human PTB rabbit polyclonal antibody, kindly provided by Chris 
Smith’s lab, 35 µL of Protein A-Sepharose® 4B beads (Fast Flow from Staphylococcus 
aureus; Sigma-Aldrich) and 130 µL of Buffer D (20 µM HEPES pH 7.9, 0.2 mM EDTA, 
20% glycerol, 0.05% NP-40, 0.1 M KCl), at 4 ºC, overnight. Samples were centrifuged 
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at 2000 rpm for 10 sec and the supernatant was discarded, and the pellet was washed 
three times with Binding Buffer I (20 µM HEPES pH 7.9, 150 µM NaCl and 0.05% 
Triton X-100) and II (20 µM HEPES pH 7.9, 150 µM NaCl and 0.4% Triton-X-100).  
 
Five µL of the inputs and the IP reaction were loaded on a 12% SDS-PAGE. 
Gels were fixed for 20 min at room temperature in a fixing solution, dried and exposed 
to a high performance chemiluminescence film (GE Healthcare). 
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Name Sequence (5’ – 3’) 
Poly(dT) adaptor primer GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTVN 
Universal anchor primer GACCACGCGTATCGATGTCGAC 
RACE Fw 1 CATGGGGCTCAGAGGCTGTA 
RACE Fw 2 AACTGGGATCCATGAGCAAAAAG 
RACE Kit Fw 1 CCCCAAAACAAGCAGCCTTCCAACTA 
RACE Kit Fw 2 TTCTCCTCAGACTCTGTCCCTGGTAA 
M13 Fw AGCATCAAATGGCGTGGAGA 
M13 Rev AGCATCAAATGGCGTGGAGA 
Total pA Fw CGGACAACTGGGCTCCTTCT 
Total pA Rev GCCTTGTCGTTGGAGGTGTT 
pA2+3 Fw CTCCCCAACCCCCTCATCTA 
pA2+3 Rev GGTTTACTAGGCGCCCCTTT 
pA3 Fw TCTGATCAAGGGAGAGGCCA 
pA3 Rev AGCATCAAATGGCGTGGAGA 
18S Fw GCAGAATCCACGCCAGTACAAGA 
18S Rev CCCTCTATGGGCCCGAATCTT 
PTB Fw GTTGGGTCGGTTCCTGCTAT 
PTB Rev CCGTCCATGGCACACAGAG 
SRSF3 Fw ACGGAATTGGAACGGGCTTT 
SRSF3 Rev CAAAGCCGGGTGGGTTTCTA 
SRSF6 Fw TTACGAGCTGAACGGCAAGG 
SRSF6 Rev CTTCCGTAGCTGTAGCCGTC 
UV-XL Sequence 1 Fw GTAATACGACTCACTATAGGGGCGGCGTCTCAGTGAAATC 
UV-XL Sequence 1 Rev GATCCGCAGGGGTGGATGCT 
UV-XL Sequence 2 Fw GTAATACGACTCACTATAGGGCTGACCCACAGCGTCACCCC 
UV-XL Sequence 2 Rev CTCTGACTCTTGGGTTAGAA 
UV-XL Sequence 3 Fw GTAATACGACTCACTATAGGGCAGCCAGTGTCTCCCATCA 
UV-XL Sequence 3 Rev TTTTAAGTAGGCCATGGTTGCT 
Table 3. Name and sequence of all the primers used during the experimental work of this thesis. All primers from 
Sigma- Aldrich. 
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Results 
 
CD5 3’ end mapping 
The first step of this work was to map the 3’ ends of CD5 by 3’ RACE and 
confirm previous results obtained with MOLT-4 cells [104]. Two pA sites were already 
identified in PolyA_DB (UCSC Genome Browser), being the most downstream one 
correspondent to the CD5 mRNA sequence NM_014207.3 at NCBI, used as reference 
for the primer design and alignments. 
The Jurkat E6.1 cell line, a human T cell lymphoblastic cell line originated from 
an acute T cell leukemia, was used to perform RT-PCR using the poly(dT) adaptor 
primer (pink box in Fig. 4) which confines the amplification only to mRNA sequences 
with a pA tail. The first 3’ RACE reaction was performed using a universal anchor 
primer, which hybridizes with the adaptor sequence of the poly(dT) adaptor primer, and 
a CD5 specific forward primer complementary to the most 3’ region of the CD5 coding 
region (see Material and Methods, primer RACE Fw1). A nested PCR was performed 
Figure 3. CD5 3’ RACE in Jurkat cells. Representative gel electrophoresis of the CD5 nested 3’ RACE using Jurkat 
cells mRNA cDNA; The white arrows indicate three CD5 pA isoforms: pA1 ~ 430 to 480 nt; pA2 ~ 850 nt; pA3 ~ 1530 to 
1600 nt; M – DNA ladder; NTC – No template control. 
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using the same anchor primer and a CD5 specific forward primer on the beginning of 
the 3’ UTR (see Material and Methods, primer RACE Fw2, and Fig. 4, blue box). The 
products were separated by gel electrophoresis (Fig. 3) and three bands are observed. 
The two longest ones have the expected sizes for the two pA sites reported in the 
PolyA_DB, and all three bands have the expected sizes of the mRNA isoforms 
identified previously in the Molt-4 cell line [104].  
The PCR product of the nested 3’ RACE reaction was cloned and sequenced, 
and the pA sites identified are represented in Fig. 4 (red arrows). All the five pA sites 
correspond to the usage of PAS already described in Molt-4 [104] (empty orange 
boxes). Also depicted in Fig. 4 are the more upstream PAS identified in Molt-4 [104] 
and the more downstream PAS associated with the longer isoform reported in 
PolyA_DB, both isoforms not obtained in this work (orange full boxes). The last isoform 
was also not sequenced in the Molt-4 work. The PAS associated with each pA site 
were identified by visual inspection of the sequence, according to spacing and 
sequence requirements (15-30 nt upstream of the pA site and hexamer AATAAA or 
variant) [42]. The different PAS were clustered in three major groups – pA1, pA2 and 
pA3. 
 
 
 
Figure 4. CD5 3’ UTR. cDNA sequence correspondent to the CD5 3’ UTR from NCBI (NM_014207.3), with the pA sites 
detected by 3’ RACE/sequence in Jurkat cells represented by red arrows, and the correspondent PAS represented by 
empty orange boxes. Full orange boxes indicate the PAS associated with the pA sites reported in Molt-4 cells (pA1a) 
and in the PolyA_DB (pA3b). Blue box - RACE Fw2; Green box - RACE kit Fw2; Pink box - Poly(dT) adaptor primer. 
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The pA1 group includes the shortest isoform (pA1a) identified in Molt-4 but not 
in Jurkat cells, and pA1b and a, both sequenced in Jurkat. All three signals are 
non-canonical and predicted weak PAS, but, as referred by Domingues, 2010, this can 
explain the close proximity between them, as a safety mechanism to ensure cleavage 
and polyadenylation in this region [104]. The pA2 PAS, ATTAAA, which is the second 
most used [44], was associated with two different cleavage sites and also with the 
upstream PolyA_DB reported pA site, referred above. Finally, the pA3 group includes 
the pA3b PAS, associated with the downstream pA site deposited in the PolyA_DB 
database, and the pA3a PAS, both presenting the canonical sequence, AATAAA. For 
simplicity, the three groups of pA isoforms will be referred as pA1, pA2 and pA3. 
 
The Jurkat cell line was the chosen biological model, because of the 
convenience of using a cell line comparative to primary cells. But in order to strengthen 
our results, 3’ RACE was also performed in human primary T cells, in order to 
investigate if the three major groups of CD5 mRNA isoforms identified in Jurkat cells 
were also present in these cells. Also, it has been reported that proliferative cellular 
states such as induced pluripotent stem cells [54] and, particularly relevant for this 
work, activated T cells [53], were associated with general shortening of the 3’ UTR 
length. Therefore, 3’ RACE was also performed in PHA activated primary T cells in 
order to compare the CD5 mRNA isoform pattern in these cells comparing to resting T 
cells. These 3’ RACE reactions were performed using the SMARTerTM RACE cDNA 
Amplification kit (Clontech), with the RACE kit Fw1 (first reaction) and RACE kit Fw2 
(nested reaction) primers (green box in Fig. 4). The nested reaction products were 
separated by gel electrophoresis and a representative picture is depicted in Fig. 5, 
where the same three major pA isoforms can be seen in all three cases, without 
significant differences between the two cell types and the different cellular conditions, 
resting and activated. The band correspondent to the pA1 isoform appears as a large 
diffuse band duo to the different isoforms composing it and the longer extension time 
applied to amplify the longer isoforms. 
All the results from the 3’ RACEs taken together indicate that the CD5 APA 
mRNA isoforms pattern is constant between the two different human leukemia cell 
lines, Jurkat and Molt-4, and human primary T cells, and between activated and resting 
primary T cells. Although is clear that the three major isoforms are expressed in all 
conditions, the 3’ RACE is not a quantitative method, for which we cannot infer if the 
expression of the different isoforms is maintained or varies.   
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Figure 6. Human CD5 3’ UTR conservation pattern of 46 species of vertebrates, from PhyloP in the UCSC Genome 
Browser. The positive blue peaks represent conserved regions and the negative red peaks represent fast-evolving 
regions. The three PAS (pA1, 2 and 3) are located in conserved regions, lacking fast-evolving peaks, and particularly 
the pA1 PAS presents strong positive conservation peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD5 3’ UTR conservation 
The PhyloP method, from UCSC Genome Browser, was used to analyze the 
conservation pattern using 46 species of vertebrates (Fig. 6). Blue positive peaks 
represent conserved sequences while the red ones represent fast-evolving sequences. 
The CD5 3’ UTR sequence is poorly conserved, yet presents some points of 
conservation, such as the regions of the three PAS which lack fast-evolving peaks, 
particularly the pA1 PAS that is located in a region with also strong peaks of high 
conservation.  
 
 
Figure 5. CD5 3’ RACE in Jurkat and primary T cells. Representative gel electrophoresis of the CD5 nested 3’ RACE 
using resting Jurkat cells, and resting and 24h PHA activated human primary T cells; The three major CD5 APA mRNA 
isoforms are present in all conditions and are indicated: pA1 ~ 110 to 160 nt; pA2 ~ 530 nt; pA3 ~ 1200 to 1280 nt; 
M - DNA ladder; NTC – No template control. 
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In order to analyze with more detail the CD5 3’ UTR conservation, the Geneious 
v4.8 software [105] was used to perform the alignment of seven CD5 genomic 
sequences from Ensembl of representative mammalian species: human (Homo 
sapiens), chimpanzee (Pan troglodytes), gorilla (Gorilla gorilla gorilla), pig (Sus scrofa), 
elephant (Loxodonta africana), dog (Canis lupus familiaris) and mouse (Mus 
musculus). The conservation percentages – pairwise percentage identity – are 
obtained from the scoring of each pair of bases of the same column, divided by the 
total pair number (Geneious 7.0 Manual at www.geneious.com). 
 
 
 
 
 
 
Figure 7. Human CD5 PAS and RBPs binding sites conservation in the CD5 3’ UTR, with pairwise % identity indicated. 
a. The six PAS alignment using the Geneious v4.8 software with seven mammalian species CD5 genomic sequences. 
The pA1b and c PAS show the highest conservation and the pA3a and b PAS show the lowest conservation. 
b. Conservation of PTB and hnRNP A1 predicted binding sites, as examples of several high conserved sequences 
throughout the CD5 3’ UTR. 
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The alignment of the six PAS in Fig. 7a clearly shows a higher conservation of 
the pA1 and pA2 PAS comparing to the pA3 PAS. The pA1b and c are the most 
conserved PAS, with 78.7% and 81.0% pairwise identities, respectively, while pA1a 
and pA2 present 72.2% and 73.8%, respectively. The least conserved PAS are pA3a 
and b, with only 65.1% and 30.1% identity. Moreover, the regions surrounding the pA1 
PAS are strongly conserved, and the fact that these are predicted weak signals may be 
overcome by the strength of the up and downstream elements, USE and DSE. 
 Other specific sequences throughout the CD5 3’ UTR show high conservation, 
including RBPs binding sites predicted by the SFmap online tool (described in 
Predicted RBPs binding sites), such as PTB or hnRNP A1 (Fig. 7b), and other regions 
that were not identified but may be important regulatory sequences. 
 
 
CD5 APA isoforms expression 
To further characterize the three major CD5 mRNA isoforms, their expression 
was measured by RT-qPCR in human primary T cells and in the E6.1 Jurkat cell line. 
Since the three isoforms do not differ in their sequences except for the extra length of 
the 3’ UTR, the primers were designed targeting these areas. Therefore, the Total pA 
primer pair is located between exon 2 and 3 and amplifies all the CD5 mRNA isoforms, 
i.e., total mRNA levels, the pA2+3 primer pair is located between the pA1 and pA2 PAS 
and amplifies the pA2 and pA3 isoforms, and the pA3 primer pair is located between 
the pA2 and pA3 PAS and amplifies the longer isoform (Fig. 8). 
 
 
 
Figure 8. Schematic representation of the CD5 pre-mRNA and mature mRNA isoforms, with the designed primer pairs 
indicated. Dotted lines - introns; Dark boxes – 5’ and 3’ untranslated regions; Light boxes – exons and coding sequence 
(CDS); Vertical arrows - pA signals; Horizontal arrow heads - forward and reverse primers. 
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The relative expression (see Material and Methods) of the CD5 APA mRNA 
isoforms was measured in human primary T cells and Jurkat cells, in resting state. The 
results include three individual experiments for each cell type.  
 
 
 
 
 
 
Primary T cells showed a strong difference between the total mRNA expression 
and the two longer isoforms (pA2 and pA3 together represent ~20% of the total mRNA) 
for which it can be concluded that the pA1 isoform is the most expressed (Fig. 9a and 
c). Also, the expression of pA2 and pA3 isoforms together is four times higher than the 
pA3 individual, which indicates that the last isoform is the least expressed of the three 
representing slightly above 5% of the total mRNA. In Jurkat cells, the levels of total 
Figure 9. The RT-qPCR results show that the CD5 pA1 mRNA isoform is the most expressed and the pA3 is the least, 
both in primary and Jurkat T cells. a. Relative expression of the CD5 APA mRNA isoforms, in resting primary T cells. 
b. Relative expression of the CD5 APA mRNA isoforms, in resting Jurkat cells. c. Ratios between the relative 
expression values of the pA2+3 and pA3 primer pairs and the Total pA pair, in primary T cells. d. Ratio as described in 
c., in Jurkat cells. * p ≤ 0.05, ** p ≤ 0.01. 
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mRNA and pA2+pA3 are not so disparate as in primary T cells, but the pA1 isoform is 
still the most highly expressed one, since pA2 and pA3 together represent less than 
35% of the total mRNA (Fig. 9b and d). As for the pA3 isoform, it only represents ~1% 
of the total mRNA and less than 3% of pA2 and pA3 together.  
Altogether, these results showed that the pA1 isoform is the most expressed of 
the CD5 APA mRNA isoforms, followed by pA2. The pA3 isoform presented very low 
levels, so the more significant difference between the two cell types is the proportion of 
pA1 comparing to pA2.  
 
 
CD5 APA and T cell activation 
As mentioned in Introduction, CD5 is an important regulator of the T cell 
activation. Therefore, one of the aims of this study was to investigate if this process 
was associated with the CD5 APA. First, the activation with PHA for 24h in Jurkat cells 
was confirmed by flow cytometry using an anti-CD69 antibody as activation control. 
This molecule was described as an early lymphocyte activation marker having its peak 
at 24h with a PHA activation [106]. The surface protein levels of CD5 were also 
measured in resting and activated cells, in order to compare these results with previous 
studies [104, 107]. 
 
 
 
Figure 10. CD5 protein surface levels increase upon activation. Representative graphics of one of the three 
independent flow cytometry experiments performed in resting and 24h PHA activated Jurkat cells, with fluorescently 
labeled anti-CD69 (a) and anti-CD5 (b) Ab. Results analyzed using the geometrical mean values (tables below the 
graphs). IC refers to the isotype controls of the respective Ab. Both CD69 and CD5 surface levels increased upon 
activation. 
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The results were analyzed through the geometric mean values, which translate 
the average intensity of the fluorescent emission of the fluorescently labeled 
antibodies, using the FlowJo v. 8.8.7 software. Fig. 10 depicts one of the three 
independent flow cytometry experiments. The three results showed an average 
increase of 4-fold (± 0.75) of the CD69 protein levels with PHA incubation for 24h, 
indicating that the Jurkat cells were being activated. As for CD5, an average increase 
of 18% (± 14%) of the CD5 surface levels was obtained after 24h incubation with PHA 
(representative graph in Fig. 10). 
 
 
 
 
 
 
After confirming the activation process, the CD5 APA mRNA isoforms levels 
were measured by RT-qPCR in Jurkat cells, in order to investigate the APA pattern in 
the two different cellular conditions – resting and 24h PHA activation. For these 
reactions the same three CD5 specific pair primers (see CD5 APA isoforms 
expression) were used, with 18S as the reference gene. Using the normalized fold 
expression (see Material and Methods) values, an increase of more than 2-fold of all 
the isoforms was observed upon activation (Fig. 11a). Analyzing the ratios of relative 
expression (see Material and Methods) of the pA2+3 and pA3 primer pairs and the 
Total pA pair, confirms that the increase is consistent between the different isoforms, 
indicating the same APA pattern in both conditions (Fig. 11b). 
 
 
Figure 11. The RT-qPCR results show a general increase of the CD5 mRNA isoforms levels upon 24h PHA activation, 
in Jurkat cells. a. Normalized fold expression of the CD5 APA mRNA isoforms upon activation. All primers showed an 
increased expression of over 2-fold upon activation. b. Ratios between the relative expression values of the pA2+3 and 
pA3 primer pairs and the Total pA pair, in Jurkat resting and activated cells. The ratios did not differ upon activation. 
FCUP 
Regulation of alternative polyadenylation in T cells 
34 
 
CD5 APA and chromatin state 
It has been described that one of the levels of regulation of the APA mechanism 
is the epigenetic modifications, namely, by specific chromatin structures and histone 
modifications. To investigate if the CD5 APA could be influenced by alterations in the 
chromatin structure, human primary T cells were incubated with TSA (Trichostatin A) 
for 1h and the RNA from the nuclear fraction was extracted.  Three independent 
experiments were performed with RT-qPCR reactions using the CD5 specific primer 
pairs described in CD5 APA isoforms expression. The TSA inhibits the class I and II 
mammalian histone deacetylases, promoting a global histone acetylation increase. 
Therefore, it “opens” the chromatin and allows it to be more easily transcribed. The 
normalized fold expressions (see Material and Methods) showed an increase of the 
pA2 and pA3 isoforms levels upon treatment with TSA, of about 20% for the pA3 
isoform and 40% for the pA2 and pA3 together, while the total mRNA levels did not 
significantly changed (Fig. 12a). The pA2+3/Total pA and pA3/Total pA relative 
expression ratios also increased, supporting the results from Fig. 12a (Fig. 12b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The RT-qPCR results show an increase of the pA2 and pA3 isoforms levels upon the TSA treatment, in 
human primary T cells. a. Normalized fold expression of the CD5 APA mRNA isoforms upon TSA treatment, relative to 
untreated cells. The pA2+3 and pA3 primer pairs showed an increased amplification of about 40 and 20%, respectively. 
b. Ratios between the relative expression values of the pA2+3 and pA3 primer pairs and the Total pA pair, in TSA 
treated and untreated primary T cells. Both ratios increased, displaying the same tendency of the results in Fig. 12a. 
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Predicted RBPs binding sites 
Several RBPs have been associated with the 3’ end processing and described 
as important factors to regulate the correct cleavage and polyadenylation [86]. 
Moreover, some have shown to influence the PAS alternative choice as its binding can 
promote or inhibit the usage of alternative PAS. Therefore, an important aim of this 
work was to identify RBPs capable of affecting the CD5 APA, in particular proteins with 
a role in the splicing mechanism. The first step was to search online databases for 
predicted RBPs binding sites in the CD5 3’ UTR, for which we used the SFmap tool 
(sfmap.technion.ac.il) [108]. Its logarithm yields a score (0 to 1) based on the 
propensity of these binding sites to be clustered and on their high evolutionary 
conservation. There are several predicted binding sites for different RBPs throughout 
the CD5 3’ UTR such as, SRSF1, 2, 3, 5 and 6, NOVA1, PTB, hnRNP A1, AB and H/F, 
Tra2α and β, or 9G8, suggesting that CD5 is a strong target of post-transcriptional 
regulation. To narrow down this list we focused on those for which we had knockdown 
resources, SRSF2, 3, 5 and 6, PTB, hnRNP A1 and AB, but only the PTB, SRSF3 and 
SRSF6 results are shown, since the other RBPs knockdown results were too 
preliminary at the time of this thesis submission. 
 
 
CD5 APA mRNA isoforms expression and RBPs 
The selected protein factors, SRSF2, 3, 5 and 6, PTB, hnRNP A1 and AB, were 
knockdown (KD) by synthetic siRNA transfection into Jurkat cells. siRNAs are 20-25 nt 
single stranded non-coding RNA molecules that target transcripts and inhibit gene 
expression by mRNA degradation or translation impairment [109]. Endogenously, long 
double-stranded RNA (dsRNA) molecules are cleaved by Dicer, which then directs the 
20-25 nt dsRNA to be assembled into the RNA-Induced Silencing Complex (RISC). In 
this complex the two strands are separated and one of them is degraded while the 
other is the guide strand that is complementary to the target sequence [110]. Synthetic 
siRNA are designed as 20-25 nt dsRNA molecules overpassing the Dicer cleavage and 
being directly assembled on RISC. 
Several important steps have to be taken into consideration when performing 
siRNA knockdown experiments. The most efficient transfection method should be 
selected for the specific target cells. For Jurkat cells, Amaxa® Nucleofection® is the 
transfection method of choice, already optimized in the lab. A careful siRNA design 
must be performed taking into account the possible unspecific targeting, targeting of all 
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isoforms and the strongest expression reduction. The last is often obtained using two to 
four siRNA for the same mRNA (General Design Guidelines by Life Technologies). 
For the following experiments two siRNA molecules were designed for each 
RBP mRNA. As a negative control, a scramble sequence, which has no homology to 
any of the target mRNAs, was used. The incubation time and siRNA concentration 
were optimized for each target, and RT-qPCRs were performed to validate the 
knockdown in every independent experiment.      
 
PTB 
PTB binds to polypyrimidine tracts and several of its SFmap predicted binding 
sites show high scores (higher than 0.8 in a 0 to 1 range, from SFmap) and high 
conservation (pairwise % identities higher than 75% from the alignment of seven 
species using Geneious v4.8). Four individual experiments of siRNA KD of PTB in 
Jurkat cells were performed, with a ~70% average decrease of PTB expression 
(Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14 shows the RT-qPCR results obtained from the PTB KD for the CD5 APA 
mRNA isoforms expression. The expression of the pA2 and pA3 isoforms together was 
increased ~14% upon PBT KD, while the total mRNA levels decreased ~16% 
(Fig. 14a). This decrease is mainly due to the decrease of the pA1 isoform, since the 
pA3 isoform levels do not showed significant differences. The wide standard deviation 
bar of pA3 is explained by the very low expression of this isoform that creates strong 
Figure 13. PTB expression decreased ~70% in the PTB siRNA KD, relative to Jurkat cells transfected with the scramble 
sequence. Relative expression of PTB of four individual experiments, using PTB specific primers and 18S as reference 
gene, normalized to the scramble value. * p ≤ 0.05. 
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variations in the normalized fold expression, even though the differences are small. 
The pA2+3/Total pA and pA3/Total pA relative expression ratios also increased 
(Fig. 14b). The first ratio is the result of the decrease in the total mRNA levels and the 
increase of the longer isoforms (pA2 and pA3). The second ratio do not suffered 
significant changes since it is only the result of the decreased of the total mRNA levels. 
These results show that PTB KD causes an increase of the pA2 isoform 
expression and a decrease in pA1. 
 
 
 
 
 
 
 
SRSF3 
The SRSF3, or Srp20, binds to polypyrimidine tracts as PTB, but also to similar 
sequences occasionally containing As or Gs instead of Us. In the CD5 3’ UTR the 
predicted binding sites for SRSF3 are uniformly distributed through its entire length, of 
which some present high scores (higher than 0.8 in a 0 to 1 range, from SFmap) and 
high conservation (pairwise % identities higher than 75% from the alignment of seven 
species using Geneious v4.8). Three individual experiments of siRNA KD of SRSF3 
were performed, with a ~66% average decrease of SRSF3 expression (Fig.15).  
 
Figure 14. The RT-qPCR results show a decrease in the pA1 isoform expression and an increase in pA2 upon PTB KD, 
in Jurkat cells. a. Normalized fold expression of the CD5 APA mRNA isoforms upon PTB KD, relative to scramble 
transfected cells. The total CD5 mRNA level decreased while the expression of pA2 and pA3 isoforms together 
increased. b. Ratios between the relative expression values of the pA2+3 and pA3 primer pairs and the Total pA pair, in 
PTB KD and scramble transfected cells. Both ratios increased in PTB KD cells.  * p ≤ 0.05. 
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The KD of SRSF3 resulted in an increase of about 70 to 90% of all primer pairs 
amplification levels (Fig. 16a). Also, the pA2+3/Total pA and pA3/Total pA relative 
expression ratios showed no significant differences in SRSF3 KD and scramble 
transfected Jurkat cells (Fig. 16b). These results indicate that SRSF3 inhibits CD5 
expression in a general manner, without having a specific effect in the APA pattern.  
 
 
 
 
 
 
Figure 16. The RT-qPCR results show an increased in the CD5 total mRNA levels without a specific effect in the APA 
pattern upon SRSF3 KD, in Jurkat cells.  a. Normalized fold expression of the CD5 APA mRNA isoforms upon SRSF3 
KD, relative to scramble transfected cells. All primer pairs showed increased amplifications of about 70 to 90%. b. 
Ratios between the relative expression values of the pA2+3 and pA3 primer pairs and the Total pA pair, in SRSF3 KD 
and scramble transfected cells. Neither of the ratios presented significant differences. 
 
Figure 15. SRSF3 expression decreased ~66% in SRSF3 siRNA KD, relative to Jurkat cells transfected with the 
scramble sequence. Relative expression of SRSF3 of three individual experiments, using SRSF3 specific primers and 
18S as reference gene, normalized to the scramble value. * p ≤ 0.05. 
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SRSF6 
The SRSF6, or Srp55, binding sites are specific hexamers, Y-R-C-R-K-M (see 
Abbreviations). The CD5 3’ UTR have only a few SRSF6 binding sites and two of those 
are located near the pA1 PAS with a 0.86 score (in a 0 to 1 range, from SFmap). Six 
independent experiments of siRNA KD of SRSF6 were performed. However, the 
efficiency of KD varied from 20 to 95% and therefore, the data must be interpreted with 
caution. Four experiments were selected to analyze the CD5 mRNA APA isoforms, in 
which the average decrease of SRSF6 expression was ~62% (Fig. 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The expression level of the pA2 and pA3 isoforms together showed a ~25% 
increase, while the total CD5 mRNA decreased ~15% (Fig. 18a). These results taken 
together indicate that the pA1 isoform expression individually decreases. Whether the 
pA2+3 increase is due to pA2 or/and pA3 increased levels, is a conclusion that cannot 
be confirmed by these data, as pA3 presents a very wide standard deviation bar 
(Fig. 18a). Both pA2+3/Total pA and pA3/Total pA relative expression ratios increased 
in PTB KD cells, due to the decrease of the total mRNA levels and the increase of the 
pA2 and pA3 isoforms (Fig. 18b). An interesting relation between the SRSF6 KD 
percentage of all the six experiments and the pA3 normalized fold expression levels 
was identified: the more efficient the KD, the higher the pA3 increase (Fig. 18c). This 
effect is clearer in KD % above 60. 
These results show that SRSF6 KD causes a decrease of the pA1 isoform 
expression and seems to lead to increase expression of the pA3 isoform. 
Figure 17. SRSF6 expression decreased ~62% in SRSF6 siRNA KD, Jurkat cells transfected with the scramble 
sequence. Relative expression of SRSF6 of three individual experiments, using SRSF6 specific primers and 18S as 
reference gene, normalized to the scramble value. 
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Specific RBPs bind the CD5 3’ UTR 
We have identified correlations between the knockdown of PTB and SRSF6 and 
differences in the CD5 APA pattern. To investigate if these results correspond to the 
binding of these specific factors to the CD5 3’ UTR, UV cross-linking assays were 
performed. This method consists in the cross-linking between proteins and nucleic 
acids through formation of covalent bonds by ultraviolet irradiation (UV). Three Jurkat 
cDNA sequences around the CD5 3’ UTR PAS (Fig. 19) were used as template to in 
vitro transcription with α-32P radiolabeled nucleotides, Us and Cs. The radiolabeled 
RNA was incubated with nuclear extracts prepared from Jurkat cells, and UV 
Figure 18. The RT-qPCR results show a decrease of the pA1 isoform and an increase of pA3 upon SRSF6 KD, in 
Jurkat cells. a. Normalized fold expression of the CD5 APA mRNA isoforms upon SRSF6 KD, relative to scramble 
transfected cells (n=4). The pA2+3 levels increase while total CD5 mRNA levels decrease. b. Ratios between the 
relative expression values of the pA2+3 and pA3 primer pairs and the Total pA pair, in SRSF6 KD and scramble 
transfected cells (n=4). Both ratios tend to increase upon SRSF6 KD. c. Relation between the normalized fold 
expression of pA3 and the SRSF6 KD efficiency % (n=6). The higher the KD %, the stronger the increase of the pA3 
isoform levels. 
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cross-linked, followed by RNase digestion. Running these reactions – inputs – in a 
SDS-PAGE gel will show all proteins that bind to the specific sequences used (see 
Material and Methods). 
 
 
 
 
The sequences to perform UV cross-linking were selected based on the 
proximity to the PAS, at least 50 to 70 nt up and downstream of the PAS, and the 
presence of important conserved and high score binding sites beyond these limits (as 
the upstream sequence of the pA1 PAS – sequence 2). Fig. 20 represents the 
predicted RBPs binding sites for PTB, SRSF3 and SRSF6, and also for hnRNP A1 and 
AB, and SRSF1, 2 and 5, contained in the three transcribed sequences, 1, 2 and 3.   
Figure 19. CD5 3’ UTR with PAS indicated with orange empty boxes and sequences used for the UV cross-linking 
assays indicated with blue full boxes. 
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From the input of the three different samples (representative gel in Fig. 21a) it 
was possible to detect some differences between them in the band pattern 
correspondent to the RNA-protein complexes. The band slightly above 37 kDa (E) can 
be identified in the sequences 1 and 3, but seems absent from 2; the band at 25 kDa 
(B) in sequence 1 does not appear in 2 and 3; the band at ~34 kDa (C) in sequences 1 
and 2 is not present in sequence 3; the band of ~35 kDa (D), in sequence 3, is not 
present in sequence 1 and 2. These results suggest that different RBPs bind to 
different CD5 RNA sequences. 
 
Part of the inputs were used to perform immunoprecipitation with an polyclonal 
anti-PTB antibody [111] (see Material and Methods). In these experiments, PTB was 
detected in sequence 1, but the same band was barely visible in sequence 2 and 3 
Figure 20. CD5 3’ UTR cDNA sequences used as template for the radiolabeled RNA transcription (without the T7 
promoter sequence represented) in the UV cross-linked assays. First and last nucleotides of the three sequences, 1, 2 
and 3, are indicated, counting from the first nucleotide of the CD5 3’ UTR. SFmap predicted binding sites for PTB, 
SRSF1, 2, 3, 5 and 6, and hnRNP A1 and AB, contained in the three selected sequences, are represented. Bold red 
characters represent the CD5 PAS. 
FCUP 
Regulation of alternative polyadenylation in T cells 
43 
 
(arrowheads in Fig. 21b). A strong background was obtained in the IP of sequence 1, 
and a very weak signal in the IP of sequences 2 and 3. This experiment must be 
repeated, although it can be affirmed that the predicted band corresponding to the 
RNA-PTB complexes is present in the three reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 21. Several different RBPs, and in particular PTB, bind the human CD5 3’ UTR, in Jurkat cells. a. Specific RBPs 
bind differently to the three PAS regions (Fig. 19 and 20). SDS-PAGE gel of the protein-RNA complexes of sequence 1, 
2 and 3, in the UV cross-linking assays. Bands marked from A to F represent distinct proteins and are referred in the 
text. b. SDS-PAGE gel of the sequence 1, 2 and 3 inputs (IN) and correspondent PTB IP reactions (IP). The PTB IP 
showed faint bands above the 50 kDa mark that may be specific for PTB. 
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Discussion/Conclusion 
 
The transmembrane glycoprotein CD5 functions as a regulatory molecule 
through its inhibitory effect in the TCR and BCR activity [21, 22, 31]. Its deregulation 
has been studied in the context of autoimmune processes and tumor immune 
response, and its role in human disorders raises the importance of studying this 
molecule, particularly at the expression regulation level. The 3’ end processing is 
essential to yield a correct mature mRNA isoform, and the selection of different PAS, 
APA, plays a major role in the regulation of gene expression [51]. Alterations on the 
APA pattern, favoring the shorter or longer isoforms, are described in different cell 
types and cellular states [52-54]. APA has also been increasingly associated with other 
mRNA processing mechanisms (reviewed in Introduction) and an important aim of this 
work was to unveil some of these interactions. CD5 is a pan-marker of T cells, so the 
biological models chosen were human primary T cells and the E6.1 Jurkat cell line. 
 
 
CD5 mRNA isoforms 
The three major CD5 mRNA isoform groups, pA1, pA2 and pA3, already 
described in Molt-4 cells, were also shown to be present in Jurkat, and in resting and 
activated primary T cells. The specific isoforms in each group were identified by 
sequencing the 3’ RACE products of Molt-4 [104] and Jurkat cells. The pA1 group 
includes three different isoforms, all using non-canonical PAS, of which the first one 
was only identified in Molt-4 cells. As for pA2 isoform, two distinct pA cleavage sites 
were identified in Jurkat cells different from the oneipredicted by PolyA_DB. However, 
all of them are defined by the same pA2 PAS which is the second most frequently used 
hexamer (AUUAAA) [44]. Finally, the pA3 group is composed by two different isoforms, 
each one using a different canonical PAS. Only the first PAS, pA3a, was identified in 
Molt-4 [104] and Jurkat cells, while the last one, pA3b, is reported in PolyA_DB. 
Quantification of the CD5 mRNA isoforms by RT-qPCR, using the primer pairs 
described in Results, does not provide the individual expression of the three mRNA 
isoforms, except for the longest one, pA3. Nevertheless, it gives insight about the 
proportions between them, and showed that the pA1 isoform is the most expressed 
while pA3 is the least, both in Jurkat and human primary T cells.  
The presence of the three pA1 putative weak PAS close to each other suggests 
that they may function together to induce transcription termination in the pA1 region 
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[104]. Furthermore, the analysis of the surrounding sequences of these PAS showed a 
strong conservation, suggesting that the auxiliary elements, USE and DSE, can 
contribute for the strength of this PAS group, a hypothesis indicated in [49]. By 
contrast, the pA3 region is the least conserved and, although presents the predicted 
strongest PAS hexamers (AAUAAA), it is the least expressed isoform. The increasing 
presumable strength of the PAS along the CD5 3’ UTR (proximal to distal) is consistent 
with previous data that showed that non-canonical PAS are frequently proximal to the 
coding region while the 3’ end pA sites usually use canonical PAS [44]. Furthermore, 
although pA1 is the most expressed, two other isoforms, with different target 
sequences for modulating factors, could account for additional posttranscriptional 
regulation, for example, in a tissue-specific manner. 
 
 
CD5 APA in transformed cells 
As mentioned before, it is widely accepted that the expression of APA isoforms 
change in different cellular conditions. For example, dividing cells have a tendency to 
use the shorter isoforms while differentiating cells use more frequently the longer 
isoforms [53, 54]. Oncogenic transformed cells are also associated with APA switch, 
favoring the usage of the shorter isoforms, proposed to be an miRNA evasion 
mechanism allowing increased protein levels [59]. 
Although pA1 and pA3 are the most and least expressed isoforms, respectively, 
in both Jurkat and human primary T cells, the proportions of CD5 APA isoforms 
between them are different. Primary T cells have a higher fraction of the pA3 isoform 
(~5%), but the two longer isoforms together, pA2 and pA3, represented only about 20% 
of the total mRNA levels. Jurkat cells, on the other hand, have a higher contribution of 
the pA2 isoform, as the pA2 and pA3 isoforms represent about 35% of the total mRNA 
with an insignificant contribution of pA3 (~1%). 
The lower percentage of pA3 in Jurkat cells is in agreement with the expected 
lower levels of the longer isoforms in transformed cells, described by Mayr and Bartel 
[59]. Moreover, several putative miRNA target sites between the pA2 and pA3 PAS, 
such as mir-7, 124, 204 and 211, can be identified in online databases (microRNA.org, 
and TargetScan.org). mir-7 is reported to be expressed in T cells (unpublished data 
and microRNA.org) so it may regulate pA3 levels, although it may not be a relevant 
biological mechanism of CD5 APA regulation, due to its scarce expression. As for the 
proportion between the pA1 and pA2 isoforms, Jurkat cells tend to privilege the usage 
of the second PAS. Previous work demonstrated higher translation efficiency for the 
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pA2 isoform over pA1 and pA3 [104], which may justify the increased percentage of 
pA2 isoform in Jurkat cells in an attempt to optimize protein production. 
 
 
CD5 APA upon T cell activation 
An important cellular condition to be addressed when working with T cells is the 
activated state. To access if this condition can modulate the CD5 APA, cells were 
incubated with PHA, which triggers the immune response rendering them activated. In 
order to confirm the activation in Jurkat cells, the surface protein levels of CD69, an 
early T cell activation marker, were measured by flow cytometry. As expected, cells 
incubated with PHA for 24h showed an average 4-fold increase. In these experiments, 
the CD5 surface levels were also determined, showing a 20% increase in activated 
cells. A similar increase was reported in a previous work, after 24h incubation with 
CD3/CD28 stimulation, showing also a 2-fold increase after 48h, in Jurkat cells [104]. A 
second study using whole-blood samples showed no significant differences in the CD5 
protein levels after 24h PHA activation [107]. 
Sandberg et al. reported an increased usage of the upstream PAS, and 
consequently a shortening of the 3’ UTRs, in murine CD4+ T lymphocytes upon 
activation by CD3/CD28 stimulation [53]. It was suggested that this could be a 
widespread mechanism, raising the possibility that it could happen in CD5. Therefore, 
CD5 mRNA levels and APA pattern were accessed by RT-qPCR in resting and 24h 
PHA activated Jurkat cells. The total mRNA levels present a ~2-fold increase in 
activated cells, which was expected [1] and in line with the higher CD5 surface protein 
levels showed by flow cytometry. As for the CD5 APA pattern, the usage of the 
different isoforms was not altered. There are at least three facts that can explain these 
contradictory results: the experiments were performed in malignant transformed cells, 
Jurkat cells, in which the molecular response upon activation can be different from 
primary T cells; the T cell activation process is different when triggered by different 
methods (PHA or CD3/CD28 stimulation); and, for CD5 in particular, it can be a 
specie-specific process of mouse cells but not human. 
 
 
CD5 APA and chromatin 
Although APA is an RNA processing mechanism, its modulation and regulation 
starts at the DNA level. Alteration of the chromatin structure modulated by histone 
modifications is an example of an APA regulation level (as described in Introduction). 
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Different chromatin condensation states can facilitate or prevent access of the 
transcription machinery, having an impact on transcription kinetics [112]. Also, an 
association between APA and RNAP II kinetics has been demonstrated, as a “slower” 
reading speed favors proximal PAS usage [80]. In order to investigate if the CD5 APA 
pattern could be influenced by histone modifications, Jurkat cells were incubated with 
TSA, which promotes a general “opening” of chromatin by increasing histone 
acetylation. The results revealed an increase in the usage of the pA2 and pA3 isoforms 
while maintaining the total mRNA levels, which indicates that the longer isoforms are 
favored over the pA1 isoform. These data suggest that pA2 and pA3 signals are 
contained in a chromatin region with generally lower levels of acetylation than the pA1 
signal, and that the increase of pA2 and pA3 mRNA levels by TSA treatment would 
allow them to be more easily accessed and recognized.  
Two complete CD5 3’ UTR maps of the acetylation mark H3K9ac (acetylation of 
histone H3 Lysine 9), a transcription activation mark [113], were accessed through the 
UCSC Genome Browser, originated by ChIP-seq (Chromatin Immunoprecipitation 
followed by high-throughput DNA sequencing) data from ENCODE/Stanford/Yale/USC/ 
Harvard (Fig. 22). These maps are from the K562 (human chronic myelogenous 
leukemia) and NT2-D1 (human embryonal pluripotent carcinoma) cell lines, since no 
information on primary or T cell lines could be obtained. Nevertheless, the two cell lines 
seem to reveal the same tendency: pA2 and pA3 PAS are located in less enriched 
H3K9 acetylation regions, comparing to pA1 region. 
 
 
 
 
 
These acetylation maps indicate that, in a normal context, the pA1 region is 
more “open” and prone to be recognized by the transcription/3’ processing machinery, 
which agrees with the fact that pA1 is the highest expressed CD5 isoform. Moreover, 
this hypothesis is supported by the TSA treatment experiments that showed an 
increase of the pA2 and pA3 levels (Fig. 23). Although all the results seem to correlate 
and suggest that histone acetylation can influence the CD5 APA, it will be important to 
characterize the general acetylation levels in T cells. 
Figure 22. Maps of the H3K9ac modification in the CD5 3’ UTR in K562 and NT2-D1 cells, with the CD5 PAS indicated. 
The grey intensity represents more (darker) or less (lighter) enriched sequences for the specific histone modification.  
Maps of ChIP-Seq data from ENCODE/Stanford/Yale/USC/Harvard (UCSC Genome Browser). The pA1 PAS is located 
in a region with higher levels of H3K9 acetylation than pA2 and pA3. 
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CD5 APA and RBPs 
An increasing number of studies have associated alternative polyadenylation 
with protein factors commonly known for their functions in other processes (reviewed in 
Introduction). An important aim of this work was to identify RBPs that influence the CD5 
APA, in particular proteins with splicing functions. As far as we know, CD5 only 
produces APA mRNA isoforms, not undergoing alternative splicing. This makes it a 
good candidate to study the role of splicing factors in APA, without co-occurrence of 
alternative splicing. The CD5 3’ UTR contains a myriad of predicted binding sites for 
different splicing factors, such as SRSF1, 2, 3, 5 and 6, NOVA1, PTB, hnRNP A1, AB 
and H/F, Tra2α and β, and 9G8 (SFmap). Knockdown of SRSF6 and PTB indicated an 
influence of these protein factors in CD5 APA. 
 
PTB 
The CD5 3’ UTR harbors several conserved predicted binding sites for PTB, in 
particular located in the surrounding regions of all three PAS. This protein has been 
associated with correct pre-mRNA 3’ end processing of several genes, particularly by 
promoting the recruitment of polyadenylation factors (reviewed in Introduction). In the 
C2 gene it was shown that higher levels of PTB inhibit polyadenylation by competition 
with polyadenylation factors and therefore a narrow concentration interval is required 
for PTB’s optimal effect. All reported data associates these effects to its binding to USE 
and DSE sequences.  
Recently, a role in APA shift was also described for PTB [95]. In CD5, the 
knockdown of this protein resulted in an increased expression of the pA2 isoform over 
a decrease of pA1, with no significant changes for pA3. Therefore, it seems to act as a 
Figure 23. Schematic representation of the proposed model of the chromatin structure influence in the CD5 APA. The 
pA1 PAS region presents higher levels of acetylation than pA2 and pA3, being more frequently recognized and used. 
After TSA treatment, the chromatin “opens” the more condensate pA2 and pA3 PAS regions, by the inhibition of histone 
deacetylases, and their expression levels increase. 
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stimulatory factor for the use of the pA1 PAS while having an inhibitory function on pA2 
(Fig. 24). As already described, the pA1 PAS region, including USE and DSE, is the 
most conserved, suggesting a relevant function of these sequences. On one hand, it is 
possible that PTB more easily promotes the recruitment of polyadenylation factors to 
the pA1 PAS region, and when at low levels, the pA2 PAS is favored by its supposed 
higher processing efficiency (AUUAAA). On the other hand, PTB may be competing 
with polyadenylation factors for the binding to the USE or DSE of pA2 PAS, and its 
knockdown allows this isoform to be more expressed over pA1. 
To confirm if PTB binds the CD5 3’ UTR, a UV cross-linking assay was 
performed for the three regions around each PAS, followed by PTB 
immunoprecipitation. However, the experiment was not conclusive since the bands 
were too faint, for which further experiments will be required. Nevertheless, in the three 
sequences, a ~57 kDa band was visible, correspondent to the PTB molecular weight. 
 
SRSF3 
SRSF3 (Srp20), as PTB, has several conserved predicted binding sites in the 
CD5 3’ UTR. Previously published results show that SRSF3 has a role in the 3’ end 
processing, but different studies associate it with different mechanisms, either 
transcription termination, cleavage or polyadenylation. Its knockdown promoted an 
upregulation of CD5 mRNA levels of almost 2-fold, without a particular tendency for a 
specific isoform, suggesting an inhibitory role over CD5 expression. Since all previous 
studies reported a positive effect of SRSF3 in the 3’ end processing, it would be 
interesting to study the effect of this factor in other genes and the mechanism behind 
this observation. 
In the UV cross-linking assays a ~23 kDa band was possible to identify in all 
three sequences, correspondent to the SRSF3 molecular weight. In sequence 2 the 
band was barely visible due to the global weaker signal of this sample. 
Immunoprecipitation with a specific anti-SRSF3 Ab would confirm if this band is in fact 
SRSF3.  
 
SRSF6 
SRSF6 (Srp55) has few predicted binding sites in the CD5 3’ UTR, specifically 
located near the pA1 PAS and between the pA2 and pA3 PAS. No previous studies 
have shown an involvement of Srp55 in the 3’ end processing, at the cleavage or 
polyadenylation level. Its knockdown showed inconsistent results, both in the 
knockdown efficiency and the CD5 isoform quantification. Even though, it was possible 
to identify a tendency of pA1 decrease and pA2 and pA3 increase. Moreover, the 
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higher the percentage of knockdown, the higher the pA3 increase. Therefore, it may 
exert a stimulatory effect in the pA1 PAS while having an inhibitory function on pA3 
(Fig. 24). The influence of this protein in APA is a new observation and should be 
further investigated in the future. 
 
 
 
 
 
 
 
Other RBPs 
 The UV cross-linking results provided an important support for the hypothesis 
that CD5 APA regulates CD5 expression. Not only showed that several RBPs bind to 
its 3’ UTR, but also that they do it differentially, suggesting specific functions of these 
proteins in specific PAS regions. It is also important to bear in mind that these assays 
only accessed short sequences around the three PAS and that other conserved 
binding sites are located throughout the 3’ UTR for all the proteins analyzed. Therefore, 
their function in CD5 APA may also depend on other regions of the 3’ UTR or even 
other interactions between different proteins. 
Considering the predicted binding sites from SFmap, their scores and 
conservation, accessed by Geneious v4.8, the possible identity of some of the proteins 
Figure 24. Schematic representation of the proposed effect of PTB and SRSF6 in the usage of the three CD5 PAS. 
PTB has predicted binding sites in the pA1 and pA2 proximity and plays an inhibitory regulation of pA2 and a stimulatory 
regulation of pA1. SRSF6 has predicted binding sites in the pA1 and pA3 proximity and plays an inhibitory regulation of 
pA3 and, as PTB, a stimulatory regulation of pA1. 
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detected in the UV cross-linking assays is proposed. The ~33 kDa band C, is present 
in sequence 1 and 2 but not 3, and in fact there are no predicted binding sites for 
SRSF1 (SF2/ASF), according to SFmap, in the last sequence 3. Band D, which is 
located slightly above band C (~35 kDa), seems to bind to sequence 3. This band 
could correspond to hnRNP A1, with ~35 kDa, which presents putative binding sites in 
the three sequences, although the sites in sequence 1 and 2 contain only one labeled 
nucleotide each (see Fig. 20 in Results), that may render visualization difficult. 
Searching for ~50 kDa proteins that may bind the CD5 3’ UTR, NOVA1 stood out with 
several conserved and high score binding sites in the three sequences. 
 
Taken together the results of this work, we were able to confirm that distinct 
cellular conditions, chromatin states and protein factors are able to induce differences 
in the proportions of the CD5 APA mRNA isoforms. This suggests that CD5 is 
regulated by APA, which in turn is modulated by several mechanisms that they may 
work together in a PAS specific manner. 
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Future work 
It was shown that although the CD5 APA pattern is consistent between Jurkat 
and human primary T cells, the proportions of the different mRNA isoforms vary. The 
decrease in pA3 percentage may be associated with miRNA targeting, hence levels of 
mir-7 in the two cells will be accessed, as well as new miRNAs with CD5 3’ UTR target 
sites and expression in T lymphocytes will be identified. Also, the mechanism 
explaining the higher proportions of pA2 isoform in Jurkat cells will be investigated, 
since it may unveil an important feature that could be tumor-specific.  
As APA is generally known to be tissue specific, t would be interesting to 
identify the CD5 APA pattern in other cell types, in particular B1a lymphocytes, in order 
to understand if the pattern presented is T cell specific.  
The CD5 APA isoforms expression will be also be accessed in activated and 
resting primary T cells, to compare with the results obtained for Jurkat cells. 
Maps of histone acetylation of the CD5 gene in T lymphocytes will be obtained 
by ChIP experiments, in order to confirm the higher levels in the pA1 PAS region 
compared with pA2 and pA3, as reported in other cell types in the UCSC Genome 
Browser. 
The PTB IP experiment will be repeated, in order to improve the band 
visualization, while a SRSF6 IP will also be performed. In the meantime, 
overexpression of these factors will be performed, to further complement the 
knockdown results. In the long term, it would be interesting to unveil the mechanisms 
behind PTB and SRSF6 effects. As for SRSF3, it will be knocked-down in other genes 
to investigate if its effect is widespread, and overexpression will also be performed. 
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